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a b s t r a c t
Flaviviridae are small enveloped viruses hosting a positive-sense single-stranded RNA genome. Besides
yellow fever virus, a landmark case in the history of virology, members of the Flavivirus genus, such as
West Nile virus and dengue virus, are increasingly gaining attention due to their re-emergence and inci-
dence in different areas of the world. Additional environmental and demographic considerations suggest
that novel or known ﬂaviviruses will continue to emerge in the future. Nevertheless, up to few years ago
ﬂaviviruses were considered low interest candidates for drug design. At the start of the European Union
VIZIER Project, in 2004, just two crystal structures of protein domains from the ﬂaviviral replication
machinery were known. Such pioneering studies, however, indicated the ﬂaviviral replication complex
as a promising target for the development of antiviral compounds. Here we review structural and func-
tional aspects emerging from the characterization of twomain components (NS3 andNS5 proteins) of thePolymerase
Methyltransferase
ﬂavivirus replication complex. Most of the reviewed results were achieved within the European Union
VIZIER Project, and cover topics that span from viral genomics to structural biology and inhibition mech-Flavivirus protein structure
Antivirals
VIZIER Consortium
anisms. The ultimate aim of the reported approaches is to shed light on the design and development of
antiviral drug leads.
© 2009 Elsevier B.V. Open access under CC BY license.Contents
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. Introduction
The genus Flavivirus, together with Pestivirus and Hepacivirus,
elongs to the family of Flaviviradae. Flaviviridae are small
nveloped viruses hosting a positive-sense single-stranded RNA
enome. The complete genome is 9500–12,500 nucleotides long.
t encodes a large polyprotein precursor, which is co- and post-
ranslationally processed by viral and cellular proteases into three
tructural proteins, building the capsid, and seven non-structural
roteins involved in virus replication.
.1. Emergence and re-emergence of pathogenic ﬂaviviruses
In the Flaviviridae family, the genus Flavivirus occupies a special
pacewithin the RNA virusworld. The family derives its name from
he word ﬂavus (Latin for yellow), with one prominent member
eing the yellow fever virus (YFV) a landmark reference system
n the history of virology. It was introduced in the Americas in the
6thcenturyasa consequenceof theAfrican slave trade, recognized
y Carlos Finlay as a vector-borne disease as early as 1881, before
ny virus was isolated. YFV was the ﬁrst human pathogenic virus
solated in 1927 (Staples and Monath, 2008). Although a safe and
fﬁcient vaccine designed in 1937 by Max Theiler shaped our view
n the control of viruses, there are still more than 200,000 annual
ases in Africa alone, and about 15% of the cases enter a critical
hase that only 50% of the patients survive (Ellis and Barrett, 2008).
nmore recent years,membersof theFlavivirus genusgainedpublic
isibility due to re-emergence and steadily increasing incidence,
uch as for West Nile virus (WNV) in the Americas and dengue
irus (DENV) in subtropical areas of the world.
WNV, isolated in Uganda in 1937, is endemic in Africa and
outhern Europe, but its appearance in the Americas in 1999
as followed by a rapid geographic extension from Canada to
rgentina by 2008, leaving behind thousands of deaths and dis-
bled patients (Petersen andHayes, 2008). Likewise, the four DENV
erotypes have considerably expanded their geographic distribu-
ion in recent years. With billions of people at risk, more than
0 million cases, and about 12,500–25,000 deaths annually, DENV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
is robustly emerging in a growing number of countries (Vasilakis
and Weaver, 2008). The two remaining clinically signiﬁcant ﬂa-
viviruses are the Japanese encephalitis virus (JEV) and tick-borne
encephalitis virus (TBEV), for which existing vaccines should help
reduce the current morbidity burden, mostly in Asia and central
Europe, respectively.Most ﬂaviviruses are arthropod-borne viruses
(arboviruses), transmitted either by ticks (tick-borne viruses, TBV)
or mosquitoes (mosquito-borne viruses, MBV), but a number of
ﬂaviviruses have no known vectors (NKV) and/or have been iso-
lated from infected animals without a link to any speciﬁc disease
(Table 1).
1.2. Development of ﬂavivirus treatments
There are a number of environmental, demographic and eco-
logical reasons to believe that either novel or known ﬂaviviruses
will continue to emerge. In this respect, the success of vaccina-
tion against YFV has been temperated by difﬁculties encountered
when such programs were launched against DENV. In particu-
lar, the presence of four DENV serotypes has complicated vaccine
design because incomplete protection against one serotype may
inﬂuence thediseaseoutcomeonce infection is establishedbyadis-
tinct serotype, through a process referred to as antibody-mediated
disease enhancement (Guzman and Kouri, 2008). Therefore, in
addition to vaccine design efforts, there has been a growing inter-
est in discovering drugs against DENV and WNV. For instance, a
moderate, borderline effect, whose mechanism of action is contro-
versial, was reported for the activity of ribavirin against ﬂaviviruses
(Huggins, 1989;Day et al., 2005; Leyssen et al., 2006; Takhampunya
et al., 2006). Prior to 2004 there were very few coordinated efforts
towards the design of antiﬂavivirus compounds, ﬂaviviruses being
hardly considered interesting candidates for drug design. A notable
exception has been the activity at the Novartis Institute for Tropi-6 M. Bollati et al. / Antiviral Research 87 (2010) 125–148
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disease since its ﬁrst opening (in 2003) (Gubler and Clark, 1995;
Kroeger et al., 2004). Perhaps even before the launch of the Euro-
pean Union VIZIER Project (Viral Enzymes Involved in Replication)
in October 2004, the lack of viral genomics programs was recog-
M. Bollati et al. / Antiviral Rese
Table 1
Flaviviral abbreviation.
Tick-borne viruses TBVs
Gadget Gully virus GGYV
Kadam virus KADV
Kyasanur Forrest disease virus KFDV
Langat virus LGTV
Omsk hemorrhagic fever virus OHFV
Powassan virus POWV
Royal farm virus RFV
Karshi virus KSIV
tick-borne encephalitis virus TBEV
Louping ill virus LIV
Meaban virus MEAV
Saumarez Reef virus SREV
Tyuleniy virus TYUV
Ngoye virus NGOV
Mosquito-borne viruses MBVs
Aroa virus AROAV
Bussuquara virus BSQV
Iguape virus IGUV
Naranjal virus NJLV
Dengue virus DENV
Kedougou virus KEDV
Cacipacore virus CPCV
Koutango virus KOUV
Japanese encephalitis virus JEV
Murray Valley encephalitis virus MVEV
Alfuy virus ALFV
St Louis encephalitis virus SLEV
Usutu virus USUV
West Nile virus WNV
Kunjin virus KUNV
Yaounde virus YAOV
Kokobera virus KOKV
Stratford virus STRV
Bagaza virus BAGV
Ilheus virus ILHV
Rocio virus ROC
Israel turkey meningoencephalomyelitis virus ITV
Ntaya virus NTAV
Tembuzu virus TMUV
Zika virus ZIKV
Spondweni virus SPOV
Banzi virus BANV
Bouboui virus BOUV
Edge Hill virus EHV
Jugra virus JUGV
Potiskum virus POTV
Saboya virus SABV
Sepik virus SEPV
Uganda S virus UGSV
Sitiawan virus SV
Kamiti River virus KRV
Wesselsbron virus WESSV
Yellow fever virus YFV
Nounané virus NOUV
Barkedji virus
Viruses with no known arthropod vector NKVs
Entebbe bat virus ENTV
Sokoluk virus SOKV
Yokose virus YOKV
Apoi virus APOIV
Cowbone Ridge virus CRV
Jutiapa virus JUTV
Modoc virus MODV
Sal Vieja virus SVV
San Perlita virus SPV
Bukalasa bat virus BBV
Carey Island virus CIV
Dakar bat virus DAKV
Montana Myotis leukoencephalitis virus MMLV
Phnom Penh bat virus PPBV
Batu Cave virus BCV
Rio Bravo virus RBV
Cell fusing agent virus CFAV
Tamana bat virus TABVarch 87 (2010) 125–148 127
nized as a problem for any research activity aiming at the discovery
anddesignof antiviral drugsbasedoncrystal structure information.
Indeed, since a single amino acid substitution can determine resis-
tance to a given drug, systematic benchmarking of starting genetic
material and resulting data was highly sought after. Few complete
ﬂavivirus genome sequences were known at the launch of VIZIER
(less than 30 out of >70), and the commitment to sequence the
entire Flavivirus genus in VIZIER (see below) was of key impor-
tance in the standardization of cDNA targets and their referencing
during the project.
1.3. Molecular biology of ﬂavivirus polyprotein processing and
replication: the roles of NS5 and NS3
The ∼11kb ﬂavivirus RNA genome is a positive-sense, single-
stranded, 5′-capped RNA ((+)ssRNA) that is released into the
cytoplasm immediately following cell entry. It encodes a single,
large polyprotein, which is proteolytically processed to yield three
structural proteins (envelope, E; membrane precursor, PrM; and
capsid C) and seven non-structural (NS) proteins (NS1, NS2a, NS2b,
NS3, NS4a, NS4b, and NS5). The polyprotein is cleaved co- and
post-translationally by a combination of cellular proteases of the
furin-type or other Golgi-localized proteases and the viral serine
protease embedded in the N-terminal domain of non-structural
protein 3 (NS3Pro),which requiresNS2B for its activity. NS proteins
are thought to co-translationally assemble on the endoplasmic
reticulum (ER) membranes forming the replication competent
complex, which consists morphologically distinct, membrane-
bound compartments that also differ with respect to both function
and NS proteins composition (reviewed in: Mackenzie, 2005). The
NS3 and NS5 proteins are central to the viral RC, as together they
harbour most, if not all, of the catalytic activities required to both
cap and replicate the viral RNA. NS3 is a multidomain protein,
with an N-terminal NS3Pro as discussed above, and a C-terminal
portion containing the RNA triphosphatase (NS3RTPase) and RNA
helicase (NS3Hel) activities involved in capping and viral RNA
synthesis, respectively. NS5 consists of anN-terminalmethyltrans-
ferase (NS5MTase) domain and the C-terminal RNA-dependent
RNA polymerase (NS5RdRp) domain. During these processes, the
(+)ssRNA viral genome acts as a template for: (1) the synthesis
of the intermediate (−)ssRNA strand by the NS5 RdRp, which in
turn acts as template solely for the synthesis of (+)ssRNA genomic
RNAs (again by the NS5), and (2) the synthesis of the viral polypro-
tein.
The 5′-end of the (+)ssRNA genome is decorated by a RNA cap
structure (N7meGpppA2′Ome-RNA). It plays an essential role, act-
ing, as for eukaryotic mRNAs, to initiate the process of translation
and to protect the viral RNA from degradation by endogenous RNA
exonucleases. It is also a unique feature of the ﬂavivirus genome in
the context of the Flaviviridae family as a whole, since pesti- and
hepaciviruses do not possess it. In ﬂaviviruses, mRNA capping is
thought to start with the conversion of the 5′-triphosphate mRNA
into adiphosphateby theRNA triphosphatasedomainembedded in
the C-terminal domain of the NS3 protein (NS3RTPase). The second
reaction is the transfer of a guanosine monophosphate (GMP) moi-
ety from a guanosine triphosphate (GTP) to 5′-diphosphate RNA,
to yield G5′-ppp-N, by a guanylyltransferase (GTase). Afterwards,
the transferred guanosine moiety is methylated by the N-terminal
methyltransferase domain of the NS5 protein (NS5MTase). To date,
the molecular species responsible for the GTase activity remains
unknown (Ahola andKaariainen, 1995; Furuichi and Shatkin, 2000;
Egloff et al., 2002; Ray et al., 2006), although recent evidences sug-
gest that it might be associated to the NS5MTase domain (Egloff et
al., 2007; Bollati et al., 2009b).
Although the details of ﬂavivirus replication have seen major
advances in the past years, many aspects remain not fully under-
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tood. For instance, an increasing number of studies have shown
hat speciﬁc RNA structures present in the 5′ and 3′ UTR regions
lay a critical role in replication and capping, with genome cycliza-
ion being one of several processes identiﬁed on which replication
epends. However, the precise details, such as how NS5 and/or
S3Hel activities might be controlled by such structures, remain
o be established. Equally, the role of NS3Hel in these processes
emains to be established formally and hence, analyzed in more
etail, although it is thought to be at least involved in the forma-
ion of the 5′ cap structure of viral RNA and in the unwinding of
sRNA intermediates that arise during replication. Observations
uch as those showing that NS3Hel has an apparently unrelated
unction in the downstream assembly of the virion indicate that
any aspects of NS3 as well as NS5 function remain to be estab-
ished.
Following replication the protected, genomic RNA is packaged
y theCprotein inahost-derived lipidbilayer inwhich theEprotein
s embedded. The mature particles subsequently exit from the host
ell by exocytosis.
.4. The VIZIER context
At the start of the VIZIER Project, crystal structures of only two
avivirus replication protein domains (DENV NS3Pro, Murthy et
l., 1999; and the DENV NS5MTase, Egloff et al., 2002) were known.
n addition to their biological relevance (discussed below) these
tudies had a pioneering value since they showed that individual
omains of NS3 and NS5 could be produced in isolation and their
rystal structure solved.
As a result, ﬂavivirus NS3 and NS5 proteins were held as targets
or the VIZIER Project. On one hand, NS3 and NS5 constitute impor-
ant drug targets, and on the other they were held s targets within
each for large scale production and crystallization, thereby facili-
ating the cementing of the VIZIER community, the beta-testing of
he communication protocols and project pipelines, and the estab-
ishment of bridges between the structural biology and virology
aboratories expertises.
In the following sectionsof thispaper,wewill present the collec-
ive efforts developed for the characterization of several ﬂavivirus
olecular aspects within the VIZIER Project (http://www.vizier-
urope.org/), from viral genomics to structural biology approaches
ocused on ﬂavivirus NS3 and NS5, emphasizing the implications
hat the data produced bear for antiviral drug development.
. Flavivirus genomics
The ﬂaviviruses comprise a fascinating group of viruses, occu-
ying a very special position in the history of virology due to
heir taxonomic, epidemiological and pathogenetic characteristics,
hich include the following:
1) The genus Flavivirus, contains an unusually large number of
viruses (more than 70), that are distributed globally. The genus
also includes a large, and increasing, number of unclassiﬁed or
“tentative” species that have very different characteristics from
those currently recognized as members of the genus.
2) Among the ﬂaviviruses there are more than 40 human
pathogens, responsible for a variety of diseases ranging
from poorly speciﬁc pseudo-ﬂu-like syndromes, to severe
encephalitic or hemorrhagic disease. One ﬂaviviral disease of
particular note is dengue fever, which is estimated to cause
in excess of 50 million cases per year (WHO, Fact sheet No.
117, March 2009). Many other ﬂaviviral diseases, such as West
Nile fever, Japanese encephalitis, and Zika fever are classiﬁed
as emerging diseases.arch 87 (2010) 125–148
(3) YFV is the prototype species of the genus ﬂavivirus. The 17D
vaccine is one of the most efﬁcient vaccines ever developed
and was derived from a strain of YFV isolated from a man who
recovered from infection by the virus.
(4) Flaviviruses are “complex” viruses, with various – and poorly
understood – ecological cycles. Importantly, most of the
human pathogens are transmitted by arthropods (i.e. they
are “arboviruses”). However, viruses with no known vector,
or viruses that infect only arthropods (tentatively referred to
as “insect-only” ﬂaviviruses) have also been identiﬁed. This
remarkable diversity is associated with broad genetic variabil-
ity and complex mechanisms of pathogenesis.
(5) The genusﬂavivirus underlines thehistory ofmammalian virol-
ogy since the ﬁrst human viral pathogen to be demonstrated as
a ﬁlterable agent was YFV (Reed, 1901a,b) and subsequently
the ﬁrst human viral pathogens isolated experimentally were
YFV (Theiler, 1930) and Louping ill virus (LIV) (Greig et al.,
1931), followed soon after by DENV and African horse sickness
virus.
(6) Flaviviruses have historically been associated with changes in
taxonomy that reﬂected advances in virology. Firstly, the term
arborviruses (subsequently changed to arboviruses to avoid
confusion with the Latin word “arbor”, meaning tree) was
derived as a taxonomic criterion following the discovery of
several arthropod-borne viruses. Subsequently, morphological
information obtained using electron microscopy supported the
hypothesis of the existence of at least two virus groups:
• One group includes non-enveloped viruses, which currently
are classiﬁed within the family Reoviridae (genera Orbivirus,
Coltivirus and Seadornavirus), i.e. viruses with an overall diam-
eter of 60–80nm, icosahedral symmetry and several concentric
capsid layers that surround a segmented double-stranded RNA
(dsRNA) genome.
• A second group includes enveloped viruses (inactivated by ether
and deoxycholate), 50–60nm in diameter, with an infectious
ssRNA genome of positive polarity. The development of serologi-
cal methods led to the identiﬁcation of two antigenically distinct
sub-groups. This division was subsequently conﬁrmed by anal-
ysis of the genome sequences and the viruses were divided as
follows:
(a) The “Group A arboviruses”, comprising viruses currently
classiﬁed within the genus Alphavirus, family Togaviridae
(together with the non-arboviral genus Rubivirus).
(b) The “Group B arboviruses”, comprising viruses currently
classiﬁed within the genus Flavivirus, family Flaviviridae
(together with non-arboviral genera Hepacivirus and Pes-
tivirus).
2.1. The ﬁrst steps in ﬂavivirus genomics
Thehistory of ﬂavivirus genomics did not startwith the progres-
sive accumulation of partial genome sequences but, surprisingly,
with the publication in 1985 of a seminal study by Rice et al.
(1985) who determined the complete genome sequence of YFV.
The work of Rice and his collaborators was remarkable because it
unexpectedly established that the ﬂavivirus genome strategy was
very distinct from that of the alphaviruses that had been grouped
taxonomically in the same virus family. Indeed, results demon-
strated the existence of 5′ and 3′ non-coding regions and, a unique
single open reading frame that encoded a polyprotein containing
all the structural proteins in the N-terminal region of the genome
and all the non-structural proteins in the C terminal region of the
genome.
This founding discoverywas followed by the rapid characteriza-
tion of a large number of complete sequences for other ﬂaviviruses:
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NV (Castle et al., 1986), JEV (Sumiyoshi et al., 1987), Kunjin virus
KUNV) (Coia et al., 1988), DENV4 (Zhao et al., 1986; Mackow et al.,
987), DENV2 (Hahn et al., 1988; Irie et al., 1989), TBEV (Mandl et
l., 1989; Pletnev et al., 1990), DENV3 (Osatomi and Sumiyoshi,
990), DENV1 (Fu et al., 1992), Powassan virus (POWV) (Mandl
t al., 1993), LIV (Gritsun et al., 1997), Murray Valley encephali-
is virus (MVEV) (Hurrelbrink et al., 1999), and Langat virus (LGTV)
Campbell and Pletnev, 2000).
This ﬁrst series of full-length genome sequences included the
rst “atypical” ﬂavivirus. In 1992, Cammisa-Parks et al. (1992)
eported the discovery and complete characterization of Cell-
usingAgent virus (CFAV). For theﬁrst time, a very distantly related
irus was studied and, importantly, results implied that the ﬂa-
ivirus lineage included viruses which infect only mosquitoes, in
ther words they are insect viruses which do not appear to infect
ammals. Togetherwith the previous isolation and antigenic char-
cterization of a number of viruses with no identiﬁed vector (i.e.
nfecting only vertebrates) such as Rio Bravo virus (RBV) (Burns
t al., 1957; Johnson, 1957), this provided robust evidence that
he ecological and genetic complexity of the ﬂaviviruses had been
nder-estimated.
.2. E gene and NS5 datasets
In parallel, studies of partial sequences commenced, focusing
ainly on ﬂavivirus E genes. Increased availability of E gene data
nabled the construction of the ﬁrst robust phylogenies for the
enus. Importantly, these studies globally conﬁrmed the previous
lassiﬁcation of ﬂaviviruses (Porterﬁeld, 1980; Calisher et al., 1989)
ased on antigenic relationships (Blok et al., 1992; Lewis et al.,
993; Mandl et al., 1993; Zanotto et al., 1996), but also established
ilestone observations regarding ﬂaviviral evolution. In particu-
ar, they suggested that TBVs and MBVs evolved independently
rom a common ancestor, that viruses belonging to the tick-borne
ncephalitis complex evolvedas anarboviral cline across thenorth-
rn hemisphere, and that, within the group of MBVs, the lineage of
ulex spp.-associated ﬂaviviruses emerged from that of Aedes spp.
ssociated viruses.
In 1998, Kuno et al. (1998) published a genetic study based on
artialNS5RdRpsequences. For theﬁrst time,phylogenies included
very large number of ﬂaviviruses from different genetic or eco-
ogical groups, i.e. MBVs and TBVs, also in addition to NKVs, plus
FAV. This study conﬁrmed the major ﬁndings of previous E gene
hylogenies, but also led to clariﬁcation of the two different groups
f NKV: one that constitutes a large independent lineage (e.g. RBV,
poi virus (APOIV), Bukalasa bat virus (BBV), Modoc virus (MODV),
tc.) and one that is related to YFV,within the group of Aedes-borne
iruses (Entebbe bat (ENTV), Yokose (YOKV) and Sokuluk (SOKV)
iruses).
.3. Recent advances in ﬂavivirus genomics
.3.1. Sequencing methods
Most complete ﬂaviviral sequences characterized to date have
een produced using complementary DNA clone(s) of the viral
enome, or, more recently, following overlapping PCR ampliﬁca-
ions along the viral genome. The latter method was optimized
ithin the framework of the VIZIER Project: the LoPPS method, a
hotgun-based approach applied to long PCR ampliﬁcation prod-
cts, was proven to be cost-effective and enabled the complete
equencing of large PCR products in a high-throughput for-
at (Emonet et al., 2006, 2007). More recently, high-throughput
yrosequencing methods (Margulies et al., 2005) have shown
otential for the rapid characterization of viruses produced in cell
ultures.arch 87 (2010) 125–148 129
2.3.2. Sequencing of previously discovered ﬂaviviral species
Since the year 2000, signiﬁcant progress has been made in
the ﬁeld of ﬂavivirus genomics. Billoir et al. (2000) produced the
ﬁrst complete sequences of NKVs (i.e. APOIV and RBV). This was
followed by the characterization of other NKVs: the MODV and
Montana Myotis leukoencephalitis viruses (MMLV) (Charlier et
al., 2002; Leyssen et al., 2002), YOKV (Tajima et al., 2005) and
EBV (Kuno and Chang, 2006). The highly atypical Tamana bat
virus (TABV) was also characterized. TABV was isolated in 1973
in Trinidad from a Pteronotus parnelii bat (Price, 1978) and its tax-
onomic position remained unresolved for nearly 30 years. Genome
sequencing ﬁnally revealed that the virus was clearly, but very dis-
tantly, related to other known ﬂaviviruses (de Lamballerie et al.,
2002). The evolutionary relationship of this virus (which chroni-
cally infects bats and has no known vector) with other ﬂaviviruses
remains unclear. Complete sequences were also established for
a number of “classical” arboviruses within the genus: St. Louis
encephalitis virus (SLEV) (Billoir et al., 2000), Usutu virus (USUV)
(Bakonyi et al., 2004), Iguape (IGUV), Bussuquara (BSQV), Kokobera
(KOKV) and Ilheus (ILHV) viruses (Kuno and Chang, 2005), Alfuy
virus (ALFV) (May et al., 2006), Sepik virus (SEPV) (Kuno and Chang,
2006), Kedougou (KEDV), Zika (ZIKV) and Bagaza (BAGV) viruses
(Kuno and Chang, 2007), and Rocio virus (ROCV) (Medeiros et al.,
2007).
The VIZIER Project has enabled full-length genome characteri-
zation of all previously identiﬁed ﬂavivirus species. The analysis of
all tick-borne ﬂavivirus species (Grard et al., 2007) led to signiﬁcant
developmentof thepreviously recognized taxonomic classiﬁcation,
e.g. the creation of the Kadam TBV group, and of the Karshi virus
species, and the assignment of TBEV and LIV to a unique species
(TBEV) which included the four viral types: Western TBEV, Eastern
TBEV, Turkish sheep TBEV and LIV.
WithinVIZIER, similar studies devoted to other ﬂavivirus groups
have been conducted. In the Aedes-borne virus group, the com-
plete coding sequences of Potiskum (POTV), Saboya (SABV), Jugra
(JUGV), Banzi (BANV), Uganda S (UGSV), Bouboui (BOUV), Edge
Hill (EHV), Sepik (SEPV), Wesselsbron (WESSV), Kedougou (KEDV),
Zika (ZIKV) and Spondweni (SPOV) viruses have now been estab-
lished or veriﬁed (Grard et al., in press). In the group of Culex-borne
viruses (Moureau et al., unpublished data), the complete coding
sequencesofAroa (AROAV), Stratford (STRV),Naranjal (NJLV), Israel
Turkey (ITV), Ntaya (NTAV), Sitiawan (SV), Tembuzu (TMUV), Caci-
pacore (CPCV), Koutango (KOUV) and Yaounde (YAOV) viruses
have been characterized. In the case of the NKV ﬂaviviruses
(Moureau et al., unpublished data), the sequences of Sokuluk
(SOKV), Bukalasa bat (BBV), Dakar bat (DAKV), Batu cave (BCV),
Phnom Penh bat (PPBV), Carey Island (CIV), Cowbone Ridge (CRV)
and Sal Vieja virus (SVV) were obtained. In all cases, the addi-
tional information has enabled new, further analyses of a large
panel of ﬂaviviral species to be performed and provided relevant
information regarding taxonomic classiﬁcation and evolutionary
relationships.
2.3.3. Newly discovered ﬂaviviruses
In recent years, a number of interesting atypical viruses related
to known ﬂaviviruses have been identiﬁed:
THE CFAV GROUP—A second virus related to CFAV, Kamiti River
virus (KRV), was isolated in 2003 from African Aedes Macintoshi
mosquito (Crabtree et al., 2003; Sang et al., 2003). Subsequently,
ﬁeld isolates of CFAV were identiﬁed from New World Aedes and
Culex mosquitoes (Cook et al., 2006). Recently, a new ﬂavivirus
associated with phlebotomines has been detected by molecular
biology in Algeria (Moureau et al., 2009), and another new insect
ﬂavivirus associated with Ochlerotatus caspius, Ae. vexans, Cx. thei-
leri, Anopheles atroparvus and Culiseta annulata has been detected
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in Spain (Aranda et al., 2008). An additional insect ﬂavivirus asso-
ciatedwithCulex spp. has been also described from Japan (Hoshino
et al., 2007), in Guatemala (Morales-Betoulle et al., 2008), in Mex-
ico (Farfan-Ale et al., 2009), and in both the USA and Trinidad
(Kim et al., 2009). Taken together, these studies have revealed
that the genetic and ecological diversity of CFAV-related viruses
is much higher than previously thought. Indeed, apparently such
viruses commonly infect a large range of mosquito species all over
the world and are hypothesized to be more accurately described
as “insectiviruses” (as opposed to arboviruses). The discovery of
long CFAV-related sequences inserted into the cellular genomes of
Aedes albopictus and Ae. aegypti mosquitoes (Crochu et al., 2004)
provided an unexpected and intriguing suggestion of an intimate
and complex relationship between Aedes spp. mosquitoes and
CFAV-related viruses.
NGOYE VIRUS—Another unique virus, “Ngoye virus” (NGOV), was
identiﬁed by molecular methods from Rhipicephalus ticks sam-
pled from Bovidae in Senegal. This virus has not yet been
successfully propagated in cell cultures or newbornmice (Grard et
al., 2006). It ismore closely related to “classical” ﬂaviviruses than it
is to TABV, but it also constitutes a new independent evolutionary
lineage within the genus Flavivirus.
NEW AEDES ASSOCIATED VIRUSES—Recently, Nounané virus
(NOUV) was isolated from Uranotaenia in Côte d’Ivoire (Junglen
et al., 2009) and Barkedji virus in Senegal (Dupressoir et al.,
unpublished data, GB EU078325, 2008). These viruses seem to
represent a new and distinct group inside the MBV group (more
information on Flavivirus phylogeny is reported as Supplementary
Information).
. Structure and function of ﬂaviviral enzymes
.1. The ﬂaviviral NS3 protein
The bipartite NS3Pro-NS3Hel is an enzyme central to ﬂavivirus
eplication and polyprotein processing. Dissecting the structural
nd functional properties of this protein in its full-length state
s therefore key to improving our understanding of the ﬂavivirus
ife cycle and informing the design of effective antiviral drugs.
t remains unclear why NS3 harbours several catalytic activities
ithin one polypeptide chain, however the conservation of this
rrangement across the Flaviviridae genus suggests some func-
ional relevance. Crucially, it is a matter of debate whether there
s an interplay between the catalytic activities of the individual
omains andwhether there is a functional role for the linker region,
poorly conserved, acidic stretch of residues connecting the two
omains (see below).
.1.1. NS3 protease domain
.1.1.1. Functional aspects of the NS3 protease. The 375-kDa ﬂa-
iviral polyprotein precursor is processed by host proteases and a
irus-encoded protease activity localized at theN-terminal domain
f NS3.Whereas the cleavage at the junctions C-prM, prM-E, E-NS1,
S4A-NS4B (Speight et al., 1988;Nowak et al., 1989), and likely also
S1-NS2A (Falgout and Markoff, 1995), is performed by the host
ignal peptidase located within the lumen of the ER, the remain-
ng peptide bonds between NS2A-NS2B, NS2B-NS3, NS3-NS4A and
S4B-NS5 are cleaved by the virus encodedNS3Pro. Cleavage at the
S2B/NS3 site is performed in cis, but is not necessary for protease
ctivity (Leung et al., 2001; Bera et al., 2007). Thus, the protease
ctivity of NS3 is essential for viral replication and its inhibition
as to be considered as a valuable intervention strategy for the
reatment of ﬂaviviral infections.
The activity of NS3Pro is strongly dependent on the associa-
ion of a 40-amino acid region of NS2B acting as a cofactor forbrane. TheN-terminalNS3Pro domain is shown in blue, theNS3Hel domain in green.
The crystal structure of DENV4 NS2B/NS3 (PDB entry 2VBC, Luo et al., 2008a) was
used for model preparation. The NS2B protein is shown in yellow, modeled regions
are shown as dashed lines and helices anchoring the complex to the membrane.
NS3Pro resulting in the formation of a heterodimeric complex.
NS2B is a small protein (∼14kDa) with a central hydrophilic part
(residues 49–89) involved in binding to NS3, thereby fulﬁlling a
chaperone-like role in stabilizing the latter protein, and two ter-
minal hydrophobic regions responsible for membrane association
of the NS2B/NS3 complex (Fig. 1) (Chambers et al., 1991, 1993;
Falgout et al., 1991, 1993; Lindenbach and Rice, 2003; Lescar et al.,
2008). The co-localization of NS2B and NS3 in convoluted mem-
branes suggests these as the location for polyprotein processing
by NS2B/NS3Pro, whereas Golgi-derived vesicle packets (the com-
partment presumably involved in RNA replication by NS3 and NS5)
lack the presence of NS2B. Accordingly, the relevance of NS2B for
non-proteolyticNS3 activities, such as helicase, nucleoside triphos-
phatase and 5′RNAphosphatase activities located in the C-terminal
two-third of NS3, is yet unclear.
Even though the minimum requirements for proteolytic activ-
ity comprise the NS3 residues 1–160 (in WNV) or 1–167 in DENV2
(Li et al., 1999; Leung et al., 2001), the maximum activity con-
cerning WNV NS3Pro, for an optimized fusion construct containing
44 NS2B residues covalently connected via a G4SG3 linker to
the NS3Pro domain, has been observed for the N-terminal 1–184
residues (Chappell et al., 2007). Interestingly, a comparative analy-
sis of the proteolytic activity of the full-length NS3 protein (1–618)
fused to the optimized NS2B-G4SG3-linker region showed only
marginal inﬂuence of the larger C-terminal domain on the NS3Pro
kinetic parameters (Chappell et al., 2007). In contrast, studies of
WNV full-length NS2B/NS3 and full-length NS3 exhibited differ-
ent catalytic activities with respect to the unwinding of DNA and
RNA: whereas full-length NS3 is capable to unwind both DNA
and RNA templates, full-length NS2B/NS3 unwinds only RNA tem-
plates, and DNA unwinding is severely repressed (Chernov et al.,
2008). Accordingly, the NS2B/NS3Pro part restricts substrate speci-
ﬁcity of the C-terminal NS3Hel domain, however, in the absence of
NS2B, theNS3 proteinmight dissociate frommembranes and inter-
fere with host DNA after translocation into the host-cell nucleus
(Chernov et al., 2008).
3.1.1.2. Three-dimensional structures determined for NS3 protease.
In 1989, sequence and structural comparison studies of the ﬂavi-
and pestiviral genomes suggested the presence of a serine protease
related to the trypsin family, comprising a His, Asp, Ser catalytic
triad (Bazan and Fletterick, 1989; Gorbalenya et al., 1989a). One
year later, this prediction was veriﬁed for YFV NS3 by mutagen-
esis and characterization of segments of the NS3 gene (Chambers
et al., 1990). The ﬁrst crystal structure of a ﬂavivirus NS3Pro was
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Table 2
Overview about the currently PDB-deposited crystal structures of Flavivirus NS3 proteases (April 2009).
Viral Protease Resolution (Å) Ligand/inhibitor PDB entry Reference, year of publication
DV2 NS3pro 2.1 Uncomplexed 1BEF Murthy et al. (1999)
DV2 NS3pro 2.1 Mung Bean Bowman-Birk inhibitor 1DF9 Murthy et al. (2000)
DV2 NS3pro 2.1 Mung Bean Bowman-Birk inhibitor 2QID Murthy et al. (to be published)
DV4 NS2b/NS3 protease-helicase 3.15 Uncomplexed 2VBC Luo et al. (2008a,b)
DV2 NS2B/NS3pro 1.5 Uncomplexed 2FOM Erbel et al. (2006)
WNV NS2B/NS3pro 1.68 Covalently bound peptide-type inhibitor 2FP7 Erbel et al. (2006)
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escribed in 1999 (Murthy et al., 1999) for DENV2. This crystal
tructure served as a template for homology modeling studies and
nterpretation of biochemical data (Nall et al., 2004; Zhou et al.,
006). Table 2 provides an overview of the crystal structures from
avivirus NS3Pro currently available. The binding mode of a pep-
idic mung-bean Bowman-Birk inhibitor in complex with DENV2
S3Pro has been reported subsequently (see below). Even though
hese structures helped to explain various biochemical observa-
ions, such as the redundant nature of interactions formed by Arg
nd Lys residues in the S1 substrate-recognition sub-site, theywere
ubstantially different from the more relevant picture represented
y the recently described crystal structures of ﬂaviviral NS3Pro in
omplex with its cofactor NS2B (Fig. 2a and b). Accordingly, recent
tructure determination attempts were focused on the crystalliza-
ion of fusion proteins containing the hydrophilic part of NS2B and
he NS3Pro domain, linked via a glycine-rich linker (Erbel et al.,
006; Aleshin et al., 2007; Robin et al., 2009). So far, only crys-
al structures of ﬂavivirus NS3Pro from DENV and WNV have been
escribed (Table 2).
In its activated state, the ﬂavivirus NS3Pro consists of the
-terminal domain of the full-length NS3 protein and its NS2B
ofactor. The hydrophilic region of NS2B strongly interacts with
S3Pro, whereas both N- and C-terminal moieties of NS2B form
wo hydrophobic helices putatively acting as membrane anchors
Fig. 1). NS2B/NS3Pro adopts a chymotrypsin-like fold comprising
wo b-barrels, each formed by six -strands, embedding the pro-
ease catalytic triad (His51, Asp75, Ser135) in the cleft between
he two -barrels (Fig. 2a). The presence or absence of the NS2B
ofactor substantially inﬂuences the NS3Pro structure with respect
o the extension and location of secondary structure elements
Erbel et al., 2006). Notably, in the cofactor-free DENV2 NS3Pro
tructure, the secondary structure elements are either shorter or
ven absent relative to DENV NS2B/NS3Pro. In the latter protein,
he hydrophilic region of NS2B forms a link between the two b-
arrels and contributes an anti-parallel -strand to each of the
-barrels. The arrangement of the catalytic triad of theNS2B-bound
S3Pro suggests an exhaustive H-bonded network between the
atalytic residues, in particular, a single-donor–double-acceptor
three-center) hydrogen bond between His51 and Asp75, whereas
he structures lacking NS2B in the free or inhibitor-bound state
xhibit an interaction geometry where only one weak H-bond
etween His51 and Asp75 is observed (Murthy et al., 1999, 2000).
hese structural differences and the less constrained framework in
bsence of NS2B will presumably be related to the low proteolytic
ctivity described for the non-cofactor-bound NS3Pro (Falgout et
l., 1991, 1993). While cleavage of small substrates by DENV2
S3Pro is virtually not affected by the presence or absence of NS2B,
egradation of larger substrates is strongly stimulated by presence
f NS2B (Yusof et al., 2000).
Sharing a sequence identity of 50%, the overall fold observed
or the NS2B/NS3Pro from WNV and DENV2 is very similar, with
nly subtle deviations in length and location of secondary structure
lements (Aleshin et al., 2007). Interestingly, WNV NS2B/NS3Pro2GGV Aleshin et al. (2007)
2IJO Aleshin et al. (2007)
peptide-type inhibitor 3E90 Robin et al. (2009)
crystal structures presently available suggest conformational plas-
ticity of the NS2B peptide: whereas in those protease structures
hosting a small-molecule inhibitor in the active site, NS2B forms a
belt aroundNS3Pro by contributing one-strand to the N-terminal
and two-strands as-hairpinmotif to theC-terminal b-barrels, in
the unbound state, the latter -hairpin does not contribute to the
C-terminal -barrel (Fig. 2c). Instead, while the N-terminal NS2B
fragment (residues 52-58) remains associated with the N-terminal
b-barrel, the C-terminal residues form a short helical segment and
a short -strand interacting with strand B2a of NS3Pro, but the
following hairpin motif points into the solvent and interacts with
symmetry-related NS3Pro molecules. A similar fold for NS2B is
observed in the inhibitor-free DENV2 NS2B/NS3Pro, with a disor-
dered region corresponding to the b-hairpin inWNVNS2B/NS3Pro.
The reasons for this unexpected NS2B plasticity are not completely
understood (Erbel et al., 2006; Aleshin et al., 2007; Chappell et al.,
2008). Nevertheless, the fold adopted by NS2B appears relevant for
structure-based ligand design of inhibitors of WNV NS3Pro, as the
NS2B b-hairpin tip in complexed NS2B/NS3Pro partly contributes
to the formation of the S2 aswell as the S3 pockets andmay thereby
directly interact with the bound ligand (see below).
3.1.1.3. Flavivirus NS3 protease complexes with inhibitors. In order
to analyze the substrate preferenceof theproteases and to establish
the basis for structure-based drug lead design, various contribu-
tions analyzed the interaction of peptide-like ligands with the
protein active site (see Table 2). The ﬁrst complex structure of
NS3Pro lacking the NS2B cofactor described byMurthy et al. (2000)
revealed the interaction of the DENV2 NS3Pro binding pocket with
a polypeptide-type Bowman-Birk inhibitor isolated from mung
beans, this being the only structure of a complex of DENV2 NS3
available to date. Despite the absence of NS2B, the structure allows
general conclusions about the properties and ligand preference of
the NS3Pro substrate-recognition pockets. The bivalent inhibitor
possesses a lysine-head and an arginine-head, both occupying the
substrate bindingpockets of twodifferentNS3Promolecules simul-
taneously (Murthy et al., 2000). Both basic residues occupy the
S1 pocket while establishing different interactions. The NS3Pro
molecule hosting the inhibitor lysine head adopts virtual identical
side-chain conformations as observed in the inhibitor-free NS3Pro.
However, the second NS3Pro molecule exhibits strong conforma-
tional changes, particularly in the region Val126-Gly136, to adopt
a binding-competent conformation (Fig. 3). The complex structure
shows that Asp129 points either to the solvent (in the P1-Lys-
bound molecule), or interacts with the basic residue (with P1-Arg
bound) of the ligand, but the latter is involved in further charge-
assisted hydrogen-bonds in a fashion obviously compensating the
mutational loss of the interaction to Asp129 (Murthy et al., 2000).
Additionally, a comparison of both NS3Pro molecules of the DENV2
NS3Pro-inhibitor complex reveals remarkable plasticity of active
site residues (Fig. 3).
The ﬂexible behavior of DENV2 NS3Pro is not observed in the
three available WNV NS3Pro-ligand complexes, all containing the
132 M. Bollati et al. / Antiviral Research 87 (2010) 125–148
Fig. 2. Crystal structures of NS3Pro fromDENV2 andWNVviruses. (a) Overall fold of
NS2B/NS3Pro from DENV2 (PDB entry 2FOM, Erbel et al., 2006). NS3Pro is shown in
blue, theNS2B region, ordered in the crystal structure, is shown in yellow. (b) Super-
positionofDENV2NS2B/NS3Proasdepicted in (a) and the crystal structureofDENV2
NS3Prowithout the stabilizing cofactor shown in orange (PDB entry 1BEF,Murthy et
al., 1999). Remarkably, substantial differences with respect to secondary structure
elements are observed. (c) Superposition of the WNV NS2B/NS3Pro in ligand-bound
and uncomplexed state. The NS3Pro covalently linked to the inhibitor (PDB entry
2FP7, Erbel et al., 2006) is shown in blue with the cofactor and ligand colored in
orange and light blue, respectively. In the uncomplexed state (H51A mutant, PDB
entry 2GGV, Aleshin et al., 2007) shown in green, theNS2B colored in yellowexhibits
remarkable plasticity compared to the ligand-bound conformer.
Fig. 3. DENV2 NS3Pro complexed with a Bowman-Birk inhibitor from Mung Bean
(PDB entry 1DF9, Murthy et al., 2000). The representation shows a superimposition
of the two protein molecules present in the asymmetric unit and the relevant pep-
tide region of the inhibitor (lysine head, depicted in orange). The crystal structure
suggests a pronounced mobility for the region 126–136 lining the speciﬁcity pock-
ets of the NS3Pro. Particularly Asp129 (equivalent to Asp189 in trypsin) is capable
of pointing either towards the solvent or contributing to the S1 pocket.
NS2B cofactor. One of them hosts aprotinin as the inhibitory lig-
and, the other two are complexed with a peptide-type substrate
analogue covalently bound to the catalytic triad residue Ser135.
Whereas the overall structure of the three protein/inhibitor com-
plexes is very similar, in contrast to the peptidic inhibitor described
by Erbel et al. (2006), aprotinin occupies all the major speciﬁcity
pockets of the NS3Pro (S2-S2′). Additionally, it induces a catalyt-
ically competent conformation with a fully structured oxyanion
hole established by themain-chain nitrogens of Gly133 and Ser135
(Aleshin et al., 2007). In the ligand-free state, the peptide bond
between Thr132 and Gly133 is ﬂipped, thereby forming a helical
310 conformation for residues 131–135. A superposition of the two
conformations observed for the aprotinin-bound and ligand-free
states is shown in Fig. 4. Themain chain of aprotinin residues 13–19
forms antiparallel-sheet interactionswith the strands E2B and B1
of WNV NS2B-NS3Pro. In contrast, the substrate analogue inhibitor
described by Erbel et al. adopts a loop conformation supported by
favourable cation–p interactions between the P1-Arg residue and
the inhibitor benzoyl cap (Fig. 2c). The protein–ligand complexes
provide structural evidence for the strong preference for ligands
(substrate or inhibitor) comprising basic residues at the P1 and P2
sites. Next to other interactions, the properties of the S1 pocket are
governed by the salt-bridge between Asp129 and P1-Arg, aswell as
by Tyr161 contributing a face-to-face-cation stackingwith the P1
residue. Interactions with the P2 moiety are mainly contributed by
the tip of the b-hairpin formed by the NS2B cofactor whose back-
bone oxygen atoms of Asp82 and Gly83 and the Od1 atom of Asn84
act as acceptors of charge-assisted H-bonds donated by the hosted
P2-Arg residue. The latter forms an additional H-bond to Asn152
O1. A P2-Lys moiety is capable of mimicking two of these interac-
tions (H-bonds accepted by the backbone oxygen of Gly83 and by
Asn152 O1), and additionally establishes a hydrogen-bond to one
of the carboxylate oxygens of Asp75. However, replacement of the
P2-basic residue by alanine leads to a total loss of binding (Erbel et
M. Bollati et al. / Antiviral Research 87 (2010) 125–148 133
Fig. 4. Induction of the oxyanion hole in WNV NS3B/NS3Pro by the polypeptide-
type inhibitor aprotinin (for clarity, only Pro13-Lys15are shown inyellow). Residues
of the uncomplexed NS3Pro (H51A mutant, PDB entry 2GGV, Aleshin et al., 2007)
are shown as green sticks, residues of the aprotinin-bound enzyme are depicted in
blue (PDB entry 2IJO, Aleshin et al., 2007). The peptide bond Thr132-Gly133 ﬂips
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associatedwithnucleic-acidbinding andNTPhydrolysis (Caruthersnd contributes via its backbone nitrogen atom to the formation of the oxyanion
ole. H-bonding interactions between the ligand carbonyl oxygen and the backbone
itrogens of Gly133, Thr134 and Ser135 are shown as orange dashes.
l., 2006). The S1′ pocket is lined on one side by the catalytic His51
swell as byGly37, providingonly sufﬁcient space to accommodate
mall P1′ side chains such as Gly, Ser, or Thr (Aleshin et al., 2007).
he different properties and plasticity behavior of the DENV2 and
NV speciﬁcity pockets could be exploited to design substrates
ith selectivity for onlyoneof theﬂavivirusNS3Pro.Whereasprob-
ng the cleavage activity revealed a strict substrate speciﬁcity of
NV NS2B-NS3Pro, in agreement with the described mobility of
he Val126-Gly136 segment (Fig. 3), the DENV2 NS2B-NS3Pro was
ess selective and tolerated well the presence of a number of amino
cid types at either the P1′ or the P2′ site (Shiryaev et al., 2007).
Very recently, Robin et al. (2009) described a crystal structure
f WNV NS2B-NS3Pro in complex with a substrate-based tripep-
ide inhibitor capped at its N-terminus by a naphthoyl moiety and
t its C-terminal end by an aldehyde. The latter acts as an elec-
rophilic warhead for covalent inhibition. Interestingly, in one of
he two NS3Pro molecules present in the asymmetric unit, the cat-
lytic His51 side chain adopts a split conformation. One conformer
ydrogen-bonds to the aldehyde oxygen directing it for a nucle-
philic attack by the catalytic Ser from the re side, whereas the
therHis conformer, inconsistentwitha catalytic triad, points away
rom the reaction center enabling the oxyanion hole to direct the
ucleophilic attack from the side. These observations suggested a
ole for the ligand to stabilize the His in its catalytically competent
onformation.
Proteases related to the occurrence of pathobiochemical pro-
esses have raised the interest of biochemists and drug designers
or many years (Mittl and Grutter, 2006). Beneﬁting from the
nowledge thereby generated, current efforts to develop ﬂavivirus
S3Pro inhibitors suitable for clinical use are indeed promising.
ue to the increasingprevalenceof infections causedbypathogenic
aviviruses such asWNV, different types of DENV, and SLEV, devel-
pment of anti-ﬂaviviral drugs is of utmost importance (Ghosh
nd Basu, 2008). Even though lessons from the treatment of
uman Immunodeﬁciency Virus (HIV) and HCV infections show
n a dramatic way the development of escape mutations confer-
ing resistance to viral proteases upon single therapywith only one
nhibitor (Manns et al., 2007), the protease inhibitors developed do
ontribute to an efﬁcient combination therapy. Since NS2B-NS3Pro
sobviouslynot only responsible for processingof theviral polypro-
ein, but also appears to contribute to further pathogenic processes
uch as induction of membraneous structures, neurovirulence andFig. 5. The structure of DENV NS3Hel with its three domains (I red, II blue and III
green) bound to AMPPNP (left, molecule in green) and RNA (7 bases are visible:
AGACUAA in yellow), adapted from PDB entry 2JLV (Luo et al., 2008a).
cleavage of host cell proteins (see above), inhibition of the prote-
olytic activity is a promising antiviral strategy.
3.1.2. NS3 helicase domain
3.1.2.1. Functional aspects of the NS3 helicase domain. It is well
understood that RNA synthesis by the viral replication machinery
requires unwinding of the RNA secondary structure in the tem-
plate RNAs. The NS3Hel domain is held to assist in initiation of
(−)ssRNA synthesis by unwinding the RNA secondary structure in
the 3′ UTR (Takegami et al., 1995). The key role of helicase activity
in viral replication has been demonstrated through site-directed
mutagenesis (Grassmann et al., 1999; Matusan et al., 2001). Crystal
structures of the ﬂavivirus C-terminal NS3RTPase/Hel domain have
been solved for YFV (Wu et al., 2005), DENV (Xu et al., 2005; Luo
et al., 2008b) and JEV (Yamashita et al., 2008). In the context of the
VIZIER Project, three new structures have been obtained for MVEV
(Mancini et al., 2007); 1.9Å resolution), KUNV, anAustralianvariant
of WNV (Mastrangelo et al., 2007b; 3.1Å) and KOKV (Speroni et al.,
2008; 2.1Å). In particular, the KOKV NS3Hel domain features high
thermostability and good propensity to crystallize, making this an
attractive model system for structural and biochemical analysis of
inhibitor binding.
3.1.2.2. Three-dimensional structures determined for the NS3 helicase
domain. The ﬂaviviral NS3Hel tertiary structure is characterized by
three domains, each of about 130–150 amino acids (Fig. 5). The ﬁrst
two domains (domains I and II) are structurally similar, displaying
an / open sheet topology (Rossman fold), composed of six -
strands (topology1–6–5–2–4–3), surrounded by four and
three-helices, respectively. Domain III is mainly composed of ﬁve
approximately parallel -helices and two antiparallel -strands
(Fig. 5). In domain II, a -hairpin (residues 426–450) protrudes
from the core domain projecting towards domain III and is held to
be a critical element in unwinding activity (Luo et al., 2008b). The
ﬁrst two domains, likely originated by gene duplication (Caruthers
and McKay, 2002), host seven characteristic sequence motifs of the
NS3Hel superfamily 2 (Gorbalenya et al., 1989b; Cordin et al., 2006),and McKay, 2002). In particular, the conserved motifs I (GAGKTRR)
and II (DEAH), also known as Walker A (ATP phosphate-binding
loop, or ‘P-loop’) and Walker B motifs (Mg2+-binding; Walker et al.,
1982), are located in the amino-terminal region (domain I) where
1 l Rese
t
e
(
i
s
i
u
g
e
d
s
a
M
o
t
i
(
s
s
o
n
b
t
(
i
(
M
t
b
3
i
a
r
r
D
c
Y
t
w
a
i
r
2
t
C
r
f
e
o
d
i
t
b
i
l
t
i
i
e
d
f
o34 M. Bollati et al. / Antivira
hey interact with the NTP substrate and Mg2+, respectively (Xu
t al., 2005). In addition, two conserved Arg residues in domain II
Arg458 and Arg461: “arginine ﬁngers” in motif VI) are involved
n ATPase and RTPase activities (Sampath et al., 2006), and in the
tructural rearrangement that results in RNA unwinding, follow-
ng ATP hydrolysis. A similar role in coupling the ATPase and RNA
nwinding activities is played by the residues of the Ia motif, as
athered from mutagenesis studies on the KOKV NS3Hel (Speroni
t al., 2008). The central region of the NS3Hel, where the three
omains contact each other, hosts a cleft held to be involved in
sRNA binding during the helicase activity (Xu et al., 2005; Luo et
l., 2008b).
Differences between the YFV, DENV, KUNV, KOKV, JEV and
VEVstructureswere found tobe conﬁnedprimarily to the relative
rientation/distance of domain II to domains I and III, suggesting
hat movement of domain II can affect nucleic-acid translocation
n an ATP-dependent mode according to the ‘inchworm’ model
Mancini et al., 2004; Mastrangelo et al., 2007b). Such overall
tructural rearrangement was recently conﬁrmed by a detailed
tructural study on DENV4 NS3Hel, which describes the structures
f various complexes with ATP analogues and ssRNA of 12–13
ucleotides (Luo et al., 2008b) (Fig. 5). In particular, upon ssRNA
inding domain III rotates about 11◦ away from domain I with
he simultaneous narrowing the of cleft between domains I and II
12◦ rotation). The overall movement can be described as an open-
ng of both the ssRNA access site, located between -helices 2
domain II) and9 (domain III; as showed innormalmode analysis;
astrangelo et al., 2007b), and the ssRNA exit site, by the reposi-
ioning of a loop (disordered in many crystal structures) located
etween strands 3 and 4 in domain I.
.1.2.3. Characterization of helicase activity. RNA unwinding activ-
ties are assessed using a partially dsRNA molecule consisting of
14 base 3′ single-stranded tail followed by a 16 base-pair dsRNA
egion (Wu et al., 2005). Generally, NS3Hel containing longer linker
egions show higher activity than those with short linkers. The
ENV4 NS3Hel (NS3 178-end) used by Luo et al. (2008b) was trun-
ated close to boundaries shown previously for DENV, WNV and
FV to yield inactive or signiﬁcantly impaireddomainswith respect
o ATPase and helicase activities when compared to constructs
ith N-terminally extended linker regions (Li et al., 1999; Wu et
l., 2005; Xu et al., 2005). In contrast, the MVEV NS3Hel construct
ncludes a signiﬁcantly longer linker suggesting that the observed
eduction in activity for the DENV4 NS3Hel domain (Luo et al.,
008b) was due to the short linker. The reason why truncation of
he linker region can have a detrimental effect on the activity of the
-terminal domainofNS3 remainsunclear; itmayhavea functional
ole (Matusan et al., 2001), or cause structural artefacts as observed
or KUNV NS3Hel (aa186-619) which forms a dimer (Mastrangelo
t al., 2007b).
The VIZIER Project has substantially enhanced our knowledge
n ﬂaviviral NS3Hel, providing the bases for the structure-based
esign and development of speciﬁc antiviral molecules target-
ng this essential class of enzymes. The remarkable similarities in
he Hel/ATPase catalytic regions indicate that it might be possi-
le to develop compounds with a broad spectrum of activities –
.e. which are able to act on different ﬂaviviral enzymes – and/or
ead molecules that can be targeted to a speciﬁc viral enzyme
hrough minimal ad hoc chemical modiﬁcations. Medicinal chem-
stry studies on protein kinases have shown that the most effective
nhibitors are conformationally based; they exert their inhibitory
ffect through an allosteric alteration of the equilibrium among
ifferent protein conformations (Vajpai et al., 2008). Likewise,
uture drug-design studies on ﬂaviviral NS3Hel will beneﬁt from
ur improved understanding of the role of the various ﬁngerprintarch 87 (2010) 125–148
residues and of the conformational changes that underlie the cou-
pling between ATP hydrolysis and RNA unwinding activity.
3.1.3. The full-length NS3 protein
3.1.3.1. Functional aspects of the NS3 protein. Understanding the
biologically relevant functional properties of NS3 is complicated
by the fact that in infected cells NS3 acts anchored to or in close
proximity of membranes (Lindenbach and Rice, 2003), whereas
most in vitro characterization has been done in solution. Fur-
thermore, as the virus progresses towards maturation, different
protein–protein andprotein–RNA interactions occurwhich demar-
cate speciﬁc points in its life cycle, although the details remain
unclear. Polyprotein processing and replication occur in dis-
tinct, membrane-bound compartments (convoluted membranes
and vesicle packets, respectively), and in each compartment, NS3
engages with different proteins (Mackenzie, 2005). An intrigu-
ing ﬁnding has been the apparent absence of NS2B, the essential
cofactor of the NS3Pro, in vesicle packets (Westaway et al., 1997;
Mackenzie, 2005) suggesting that in the transition frompolyprotein
processing to replication, the NS3Pro becomes inactive. Finally, the
structure and dynamics of the polyprotein as it emerges follow-
ing translation remain largely unexplored and little information
exists on interactions between NS3 and other parts of the polypro-
tein, which might be important for priming NS3Pro for its ﬁrst and
subsequent cleavage activities.
3.1.3.2. Three-dimensional structures determined for the NS3 protein.
Two full-length NS3 structures have been solved by X-ray crystal-
lography: those of DENV4 NS3 (Luo et al., 2008a) and of MVEV NS3
(Assenberg et al., submitted for publication) (Fig. 6). Both struc-
tures were solved in the presence of a fragment of protein NS2B,
the essential co-factor and activator for NS3Pro, by producing a
single polypeptide chain where this region was linked via a ﬂexible
tether to NS3. One difference between the two studies is that for
DENV4 only part of the NS2B activating region was coupled to NS3
(18 amino acids of NS2B, DENV4 NS2B18NS3), whereas for MVEV
the full activating region was included (45 residues of NS2B, MVEV
NS2B45NS3).
In both theDENV4NS3 (Luo et al., 2008a) andMVEVNS3 (Assen-
berg et al, submitted for publication) structures the NS2B-NS3
molecule consists of two separate globular folds linked by a short
linker, an arrangement consistent with SAXS data for full-length
KUNV NS3 in solution (Mastrangelo et al., 2007b). The individual
domains are very similar between the two molecules (r.m.s.d. of
1.5 and 1.6Å for the NS3Hel and NS3Pro, respectively) and to the
structures of isolated domains. Yet the relative orientations of the
NS3Pro and NS3Hel domains are dramatically different between
MVEV NS2B45NS3 and DENV4 NS2B18NS3. When superimposing
the NS3Hel domains of the two structures, a rotation of ∼180◦
and translation of 17Å are required to align the NS3Pro domains.
The 13-residue “linker” between the NS3Pro and NS3Hel domains
(residues 169–181) is ordered in DENV4 NS2B18NS3 but partially
disordered in MVEV NS2B45NS3. Even though the buried surface
area between the NS3Pro and the NS3Hel in DENV2 NS2B18NS3
is only 568Å2, the NS3Pro domain and the linker loop engage
in possibly signiﬁcant interactions with subdomains 1 and 2 of
NS3Hel. Speciﬁcally, the linker interacts with the catalytic P-loop
of the NS3Hel, which assumes the distinctive apo conformation
seen in the NS3Hel domain crystal structure in the absence of
bound nucleotides. These interactions are not seen in the MVEV
NS2B45NS3 structure where the buried surface area is only 30Å2;
however, the P-loop is found in the same apo conformation. Thus,
a possible role for the linker loop could be to stabilize the apo
conformation of the P-loop, in line with recent studies suggest-
ing a functional role for the linker (truncating this acidic linker
can have a substantial effect on the activity of isolated NS3Hel
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polyprotein (Zhang andPadmanabhan, 1993), andNS3binds to freeig. 6. Comparison of the NS2B-NS3 structures of MVEV (upper panel) and DENV4
lower panel); in both panels the NS3Hel domain is in the upper part of the ﬁgure,
he NS3Pro domain is in blue–cyan colors, hosting the NS2B segment (red color).
omains; Li et al., 1999; Wu et al., 2005; Mastrangelo et al.,
007b).
A striking observation relating to the inﬂuence of the NS3Pro
omain on the NS3Hel domain emerges from a comparison of the
wo structures. In DENV4 NS2B18NS3, the interactions between
S3Pro and NS3Hel are such that motions of domain 2 of the
S3Hel, known to be important for helicase activity, would be
onstrained. In the MVEV NS2B45NS3 structure in contrast, such
nteractions are weak and therefore there are no constraints on the
otility of the NS3Hel domain. This would suggest that the NS3Pro
omainmight repress helicase activity and that such activitymight
e regulated by switching between various transient conﬁgura-
ions, such as those observed in the two structures. This conclusion
ontrasts that of Luo et al. (2008a), who saw an increased afﬁn-
ty for ATP when the activity of the DENV4 NS2B18NS3 protein
as compared to that of the isolated NS3Hel domain. Although
his enhancement was explained by a positive contribution of
he NS3Pro domain to the electrostatic potential of the NS3Hel
ucleotide binding pocket raising helicase activity, an alternative
xplanation is that the isolatedNS3Hel domain chosen for compari-
onwas ‘hobbled’ by truncation of the linker. Indeed the truncation
sed has been shown to signiﬁcantly reduce helicase activity of
ENV2 and other ﬂavivirus NS3Hel domains (Li et al., 1999; Wu
t al., 2005). The latter interpretation is supported by biochemical
nalysis of thehelicase activity ofMVEVNS2B NS3,which showed45
o signiﬁcant difference between the activity of full-length MVEV
S2B45NS3 and that of the isolated NS3Hel domain (using a more
ppropriate linker than in the DENV4 study). Finally, NS2B is not
ound in vesicle packets and therefore not part of the replicationarch 87 (2010) 125–148 135
complex (Westaway et al., 1997; Mackenzie, 2005), posing further
questions over the role of the NS3Pro domain in regulating helicase
activity since in the absence of NS2B the NS3Pro domain partially
unfolds.
3.1.3.3. General structural properties of the NS3 protein. The struc-
tures of full-length NS3 raise two important questions: (1) do these
structures represent two distinct and stable conformations of NS3
possibly adopted at different stages of the ﬂavivirus life cycle or
are they merely snap-shots of a highly dynamical interconversion
process and (2) given the segregated nature of the two catalytic
domains, what is the functional signiﬁcance of this arrangement?
Our analysis suggests that the relative domain organization is
probably highly dynamic, given the linker ﬂexibility (disordered in
the MVEV structure) and the small buried surface areas between
the two domains in both structures. Further, the conﬁgurations are
in principle inter convertable via simple rotations around the linker
loop, and linker ﬂexibility is probably paramount to the NS3 activ-
ities and its ability to associate with other proteins and RNA. On
the other hand, speciﬁc conﬁgurations may be stabilized during a
particular stage of the virus life cycle. To gain further insights into
these issues, we modeled the MVEV and DENV NS2B-NS3 struc-
tures in the presence of a membrane (Assenberg et al., submitted
forpublication). Previous studieshave shownthatwhen in complex
with NS2B, and in particular when fully activated, NS3Pro sits in a
rather tight membrane-anchored sling (Clum et al., 1997; Robin et
al., 2009). Fig. 7 showsamodel ofMVEVandDENV4NS2B-NS3,with
their NS3Pro domains superimposed and associated to the mem-
brane as inferred from the anchoring of thepublishedNS2B-NS3Pro
structures (Erbel et al., 2006; Robin et al., 2009). In this model,
the DENV4 NS2B18NS3 NS3Hel is positioned near the membrane
with the active site orientated towards the membrane and with lit-
tle space to accommodate RNA, whilst in the MVEV structure the
NS3Hel domain is positioned away from the membrane, with the
active site facing the cytoplasm. Thus, the DENV4 NS2B-NS3 struc-
ture appears incompatible with RTPase/helicase activity. Although
this could be taken as an argument that the DENV4 conformation
may not be physiologically relevant, the strength of conforma-
tional constraints imposed by the cellular environment is difﬁcult
to assess. Prior to cleavage of the NS3-NS4A junction, NS3 is also
anchored to the membrane at its C-terminus via the membrane-
bound NS4A. However, although there are 50 residues separating
the NS3 C-terminus and the ﬁrst trans-membrane -helix of NS4A
(Miller et al., 2007), the structure of the ﬁrst 50 residues of NS4A
remains unknown. Thus, the presence of NS4A may limit the abil-
ity of NS3 to change its conformation in vivo. This leads to the
interesting possibility that NS3 may adopt this conformation dur-
ing polyprotein processing where helicase activity is probably not
wanted. Formation of the replication complex, where the helicase
activity is presumablyneeded,would releaseNS2B, inactivating the
NS3Pro domain. In this view, the MVEV NS2B-NS3 conformation is
likely to be relevant later in the virus life cycle, during the assembly
and functioning of the replication complex. The regulation of the
activities of NS3 by an environment-dependent re-conﬁguration of
the molecule offers a simple temporal and spatial control mech-
anism, coupling activities appropriately with the virus life cycle.
This model provides answers to both of the questions posed in the
previous paragraph.
In vivo, the situation is probably complicated by the modulation
of the structure and function of NS3 by additional binding partners.
Thus, the activity of NS3 may be affected by interactions within theNS5 (Johansson et al., 2001; Yon et al., 2005), NS4A (Mackenzie et
al., 1998) and NS4B (Umareddy et al., 2006) as well as viral RNA.
In particular, it has been suggested that the C-terminal domain of
NS3 binds NS5 (Liu et al., 2002; Wu et al., 2005) during the forma-
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Fig. 7. Models for membrane association of MVEV and DENV4 NS2B-NS3. (a) Schematic diagram of the ﬂavivirus polyprotein organization and processing. The upper ﬁgure
shows the linear organization of the structural andnon-structural proteinswithin the polyprotein. The lower ﬁgure shows the putativemembrane topology of the polyprotein,
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ion of the replication complex. Unfortunately, the details of these
nteractions remain poorly understood. Clearly, further studies are
equired to test the functional signiﬁcance of the two conforma-
ions in vivo, as well as the inﬂuence of the interactions between
S3 and other viral proteins, RNA, and lipids on the conformation
f NS3.
The structures of full-length NS3 reveal that the molecule
an assume two radically different conﬁgurations, deﬁned by the
elative positioning of the NS3Pro and NS3Hel via a ﬂexible inter-
omain linker. We suggest that these may be important in its
nteractions with other proteins and RNA and, possibly, in mod-
lating the switch to helicase and triphosphatase activities during
eplication.
.2. The ﬂaviviral NS5 protein
With a molecular mass of about 100kDa, NS5 is the largest
aviviral protein; NS5 is also the most conserved one across the
enus. Early on a motif of AdoMet-dependent MTases was identi-
ed within the N-terminal domain of NS5 (Koonin, 1993) whereas
dRp motifs were identiﬁed in the C-terminal domain of protein
S5 (Rice et al., 1985; Poch et al., 1989; Koonin, 1991; Bruenn,
003). The MTase functions were demonstrated in 2002 and 2007
sing the recombinant N-terminal MTase domains of DENV2 and
NV (Egloff et al., 2002; Ray et al., 2006). The RdRp activity was
rst demonstrated by the use of NS5-speciﬁc antisera that inhib-
ted RdRp activity in assays using DENV2-infected cell lysates
Bartholomeusz et al., 1994), as well as by DENV1 recombinant
S5 (Tan et al., 1996). The latter bound RNA template and showed
dRp activity as detected by the incorporation of radiolabel into a
eosynthesized RNA strand (Tan et al., 1996). NS5 of ﬂaviviruses
as subsequently been expressed in various in vitro systems, andr and viral proteases (denoted by arrows). (b) Predicted structural organization of
mbrane is shown as van der Waals balls, atomic structures are shown in a surface
e yellow) and NS2B stretches (blue). The NS4A (shown schematically in pink) was
is positioned in the ssRNA binding groove.
shown to have RdRp activity (Ackermann and Padmanabhan, 2001;
Guyatt et al., 2001; Nomaguchi et al., 2003, 2004; Kim et al., 2007).
It has been demonstrated that NS5 initiates RNA synthesis de novo
(i.e. primer-independent) (Ackermann and Padmanabhan, 2001;
Nomaguchi et al., 2004; Selisko et al., 2006).
The N-terminal boundary of the RdRp domain of protein NS5,
which comprises around 900 amino acids, has long remained
unknown. Usually two nuclear localization sequences (NLS) local-
ized between amino acid residues 320 and 405 were supposed
to represent the inter-domain region between MTase and RdRp
(Brooks et al., 2002). Within the VIZIER Project, structure-based
sequence analysis of NS5 was conducted and allowed the deﬁ-
nition and subsequent production of a recombinant soluble and
enzymatically active RdRp domain of DV2 (NS5PolDV) and WNV
(NS5PolWNV) starting at DV2 NS5 residue 272 (Selisko et al., 2006).
More recently,we expressed full-lengthNS5proteins of two strains
(Vasilchencko and Oshimo) of TBEV in Escherichia coli (cloned in
pDest14 and expressed as described, Selisko et al., 2006). The
recombinant proteins were puriﬁed by IMAC followed by size
exclusion chromatography. NS5 was obtained but also to a large
extent a degradation product of around 30kDa. Western blot anal-
ysis against the N-terminal hexahistidine-tag revealed that this
pool was the N-terminal part of NS5. The mass of these proteins
were checked by matrix-assisted laser desorption ionization-time
of ﬂight mass spectrometry (MALDI-TOF) rendering a unique peak
at 30,299Da for NS5 of TBEV Vasilchenko and 30,335Da for NS5
of TBEV Oshima (data not shown). These data suggest that the
main cleavage occurs after Arg-264 or Cys-265, depending on the
presence or not of the start methionine that can be, in E. coli,
removed. In summary, we conclude that the linker region between
the MTase and the RdRp domain of ﬂavivirus NS5 can be assigned
to residues 266 to 272. Interestingly, all solved NS5MTase struc-
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Table 3
Flaviviral MTases crystal structures.
Virus PDB ID Ligand(s) Reference Vizier
WESSV
3ELY AdoHcy Bollati et al. (2009a) Yes
3ELU AdoMet Bollati et al. (2009a) Yes
3ELW AdoMet +GpppG Bollati et al. (2009a) Yes
3EMB AdoMet +N7MeGpppG Bollati et al. (2009a) Yes
3ELD Sinefungin Bollati et al. (2009a) Yes
3EMD Sinefungin +N7MeGpppA Bollati et al. (2009a) Yes
MVEV
2PX2 AdoHcy Assenberg et al. (2007) Yes
2PX4 AdoHcy Assenberg et al. (2007) Yes
2PX5 AdoHcy Assenberg et al. (2007) Yes
2PXC AdoMet +GpppA Assenberg et al. (2007) Yes
2PX8 AdoHcy+N7MeGTP Assenberg et al. (2007) Yes
2PXA AdoHcy+GpppG Assenberg et al. (2007) Yes
DENV
1L9K AdoHcy Egloff et al. (2002) No
3EVG AdoHcy Geiss et al. (2009) No
1L9K AdoHcy+Ribavirin triphosphate Egloff et al. (2002) No
2P41 AdoHcy+N7MeGpppG2′OMe Egloff et al. (2007) Yes
2P40 AdoHcy+N7MeGpppG Egloff et al. (2007) Yes
2P3Q AdoHcy+GpppG Egloff et al. (2007) Yes
2P3O AdoHcy+N7MeGpppA Egloff et al. (2007) Yes
2P3L AdoHcy+GpppA Egloff et al. (2007) Yes
YFV
3EVA AdoHcy Geiss et al. (2009) No
3EVB AdoHcy Geiss et al. (2009) No
3EVC AdoHcy+GTP Geiss et al. (2009) No
3EVD AdoHcy+GTP Geiss et al. (2009) No
3EVE AdoHcy+GpppA Geiss et al. (2009) No
3EVF AdoHcy+N7MeGpppA Geiss et al. (2009) No
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ures (see Section 3.2.1), which were obtained either from protein
onstructs consisting of about 265 or of 293 residues, comprise
pproximately 265 residues only, since the 266–293 stretch of
he long constructs are usually disordered. The only exception are
wo WESSV NS5MTase domain structures (PDB entries 3ELD and
ELU, Bollati et al., 2009b), which include the linker region and a
-terminal helix from residues 274 to 285. Interestingly, residues
67–269 are disordered, what supports our proposal of the linker
egion. The C-terminal region is nevertheless characterized by high
obility, which may be functional for the interaction between
he NS5MTase and the NS5RdRp domains of the full-length viral
rotein.
.2.1. NS5 methyltransferase domain
.2.1.1. Functional background aspects of the NS5 methyltransferase
omain. The ﬂavivirus RNA is decorated with a conserved type-
cap (N7meGpppA2′Ome-RNA) at its 5′-end, a unique structure
onsisting of an inverted guanosine linked to the ﬁrst transcribed
NA nucleotide by a 5′–5′ triphosphate bridge. Viral MTases are
nvolved in themRNA capping process, transferring amethyl group
rom the cofactor S-adenosyl-l-methionine (AdoMet) onto the N7
tom of the cap guanine and onto the 2′OH group of the ribose
oiety of the ﬁrst RNA nucleotide. In the genus Flavivirus, both
guanine-N7)-methyltransferase (N7MTase) and (nucleoside-2′-O-
-methyltransferase (2′OMTase) activities have been associated
ith the N-terminal domain of the viral NS5 protein (Egloff et al.,
002; Ray et al., 2006; Zhou et al., 2007).
.2.1.2. Three-dimensional structures determined for the NS5 methyl-
ransferase domain. Crystal structures of the NS5MTase domain
ave been reported for different mosquito-borne ﬂaviviruses, such
s DENV (Egloff et al., 2002), WNV (Zhou et al., 2007) and YFV
Geiss et al., 2009). In the context of the VIZIER Project new high-
esolution structures of NS5MTases have been obtained for MEAV,
TBV (Mastrangelo et al., 2007a), for the MBV MVEV (Assenberg etZhou et al. (2007) No
Mastrangelo et al. (2007a,b) Yes
Bollati et al. (2009b) Yes
al., 2007) andWESSV (Bollati et al., 2009b), and for twoNKVs: YOKV
(Bollati et al., 2009a) and MODV (Jansson et al., 2009) (Table 3).
Moreover, structures of DENV NS5MTase, MVEV NS5MTase and
WESSV NS5MTase in complex with GTP or several cap analogues,
GpppA/GandN7meGpppA/G (Egloff et al., 2002, 2007;Assenberget
al., 2007; Bollati et al., 2009b) havebeen reported, shedding light on
the substrate-bindingmodeduringmethylation andon the enzyme
mechanism of action (Table 3).
The ﬂaviviral NS5MTase domain consists of a 33-kDa protein
comprising residues 1–260/270 of the N-terminus of the NS5
protein. It is characterized by an overall globular fold consist-
ing of a core domain (residues 59–224) ﬂanked by an N-terminal
region (residues 1–58), and a C-terminal region (residues 225–265)
(Fig. 8). The core domain comprises a seven-stranded -sheet sur-
rounded by four -helices and two 310 helices, closely resembling
the topology observed in the catalytic domain of other AdoMet-
dependent MTases (Fauman et al., 1999; Bugl et al., 2000; Egloff
et al., 2002). The N-terminal segment comprises a helix-turn-helix
motif followed by a-strand and an-helix. The C-terminal region
consists of an -helix and two -strands (Fig. 8). The core subdo-
main hosts the active site and the cofactor binding site (Ingrosso
et al., 1989; Egloff et al., 2002, 2007; Assenberg et al., 2007;
Mastrangeloet al., 2007a;Zhouetal., 2007;Bollati et al., 2009a,b). In
all the structures a cofactor molecule, in some cases the co-product
AdoHcy, originated from E. coli and co-puriﬁed with the enzyme,
is bound in this binding site, where it is stabilized by a network
of hydrogen bonds and van der Waals contacts involving several
residues – Ser56, Gly86, Trp87, Thr104, Leu105, His110, Asn131,
Val132, Asp146, and Ile147 (residue numbering refers to WESSV
NS5MTase) – and a series of interactions that are well conserved
within the ﬂaviviruses NS5MTases (Fauman et al., 1999; Egloff et
al., 2002, 2007; Assenberg et al., 2007; Mastrangelo et al., 2007a;
Zhou et al., 2007; Bollati et al., 2009a,b).
The known ﬂaviviral NS5MTases show a large degree of struc-
tural homology (r.m.s.d. < 1Å), which reﬂects the high amino acid
138 M. Bollati et al. / Antiviral Rese
Fig. 8. Crystal structure of DENV NS5MTase in complex with AdoHcy. A ball-and-
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mtick representation is used for AdoHcy, whereas DENV NS5MTase is drawn as a
ibbon (Egloff et al., 2002). The loops differing between NS5MTases representative
f the three Flaviviral branches are highlighted with a star and an identiﬁcation
umber referring to what has been described in the text.
equence conservation (between 30% and 90%). Comparison of
he NS5MTases representative of each of the three ﬂaviviruses
ranches (the NKV, YOKV NS5MTase; the TBFV, MEAV NS5MTase,
nd the MBFV, DENV NS5MTase) shows that most differences in
he structures are caused by surface-loop ﬂexibility and amino
cid variability, displayed in four regions of the enzyme: (1) helix-
oop-helix motif in the N-terminal domain, involved in the binding
f the substrate (residues Gly21-Lys22-Thr23 in YOKV NS5MTase,
ubstituted with Gly-Lys-Ser in DENV NS5MTase, and Thr-Lys-Glu
n MEAV NS5MTase); (2) 3-X loop (Asn47-Ile53; insertion of
ne amino acid in MEAV NS5MTase); (3) D-5 loop (Leu172-
hr178; deletion of two amino acids in DENV NS5MTase); and (4)
4-8 loop (Leu246-Thr252; deletion of two amino acids in MEAV
S5MTase) (highlighted in Fig. 8) (Bollati et al., 2009a).
.2.1.3. Structures of protein/ligand complexes. In the context of
he VIZIER Project, structures of different NS5MTases in complex
ith cofactor and several capped substrate analogues have been
olved (Egloff et al., 2002, 2007; Assenberg et al., 2007; Bollati et
l., 2009b). All the complexes show that the cap guanine moiety
methylated or not) binds to a site next to the N-terminal helix-
urn-helix motif, called the high afﬁnity binding site (HBS) formed
y residues Lys13, Leu16, Asn17, Leu19, Phe24, Ser150, Arg197,
rg213, Ser215. In particular, Phe24 plays an essential role in driv-
ng the cap binding by stacking against the cap guanine base during
he interaction (Egloff et al., 2002, 2007; Assenberg et al., 2007;
astrangelo et al., 2007a; Bollati et al., 2009b; Milani et al., 2009).
he ﬁrst nucleotide after the cap is often disordered, reﬂecting a
ack of strong interactions with the enzyme. This is in line with
ther studies showing that a minimal number of nucleotides in
apped RNA are required for substrate binding and methylation
Ray et al., 2006; Egloff et al., 2007; Dong et al., 2008; Selisko et al.,
n press). A unique conformation of the cap analogue is adopted by
pppA in complex with DENV NS5MTase. The guanine is bound
n the HBS and GpppA displays an overall hairpin-like shape in
hich the two bases stack against each other in a way that allows
o accommodate a longer capped RNA because the 3′-position of
he A ribose is oriented towards a positively charged surface region
Egloff et al., 2007). It was proposed that this conformation might
imic the reaction product of a putative ﬂavivirus GTase activ-arch 87 (2010) 125–148
ity: pppG+ppAGN leading to GpppAGN+pyrophosphate. Such a
guanylyltransfer reaction would be the only occasion where the
GTP-binding site of DENVNS5MTase needs to accommodate a non-
methylated GTP.
Sinceﬂaviviral NS5MTases display bothN7MTase and2′OMTase
activities (Ray et al., 2006; Egloff et al., 2007; Zhou et al., 2007;Dong
et al., 2008), in order for capped RNA to be methylated at the two
different sites, it must adopt two distinct binding modes relative
to the enzyme active site. To date structural details on catalytically
relevant states for both N7 or 2′O methyl transfer are missing. Nev-
ertheless, it has been speculated that when the cap is bound in the
HBS, the 2′OH group of the ribose moiety of the nucleotide follow-
ing the cap is the closest atom to the AdoMet exchangeable methyl
group (Egloff et al., 2007; Mastrangelo et al., 2007a; Bollati et al.,
2009b). For this reason, the HBS is assumed to host the cap during
2′O methylation. Moreover, structural considerations suggest the
existence of a secondary, putative low-afﬁnity binding site (LBS)
located in a positively charged region close to the AdoMet binding
site which could be involved in binding the capped RNA substrate
(Egloff et al., 2007; Mastrangelo et al., 2007a; Dong et al., 2008;
Bollati et al., 2009a,b).
In this context, two differentmodels of themechanism of action
of the ﬂaviviral NS5MTase have been proposed. Model 1 (Egloff et
al., 2007; Mastrangelo et al., 2007a; Zhou et al., 2007; Dong et al.,
2008; Bollati et al., 2009a,b; Milani et al., 2009) suggests that when
the capped RNA substrate binds in the LBS, it undergoes methyl
transfer in position N7 of the guanine with the cap guanine ﬁxed in
the active site. Afterwards, the NS5MTase slides on the RNA chain
positioning the cap in the HBS and locating the ﬁrst RNA adenine
in the active site for 2′O methylation. In this binding mode, the
rest of the RNA chain is still stabilized by the interaction with the
residues of the LBS, but shifted by one nucleotide. The analysis of
conserved residueswithin ﬂaviviral NS5MTases shows that there is
an almost continuous and conserved region extending away from
the active site towards the back of the protein—residues Tyr89,
Pro113, Gly120, Trp121, Asn122, Leu123, Ile124, Phe126, Lys127,
Asp131, Gly263, Thr264 and Arg265 on the side of the NS5MTase,
and residuesAla60, Trp64, Leu207,Val208,Arg209, Pro211,Met220
and Arg244 on the back (numbering referring to YOKV NS5MTase
(Bollati et al., 2009a). This region may play a role in stabilization
of the rest of the RNA chain following the cap (no crystal struc-
ture available so far) (Bollati et al., 2009a). In order to predict the
interactions between the protein and the RNA during N7 methyl
transfer, Milani et al. presented a model of a short capped RNA
(GpppAGUp) bound to the LBS of WESSV NS5MTase (Milani et al.,
2009). The model produced after 9ns of Molecular Dynamic simu-
lation shows that the cap guanine was located close to AdoMet and
to residues Glu149 and Arg213; other residues found to interact
with capped RNA were: Arg37, Arg41, Leu44, Ser56, Arg57, Arg84,
Glu149, Lys112, Ser150, Arg160, Ser215. In line with this model,
it has been recently shown that point mutations of a good part of
these aminoacids (Arg37,Arg57,Arg84, Trp87,Glu149,Arg213, and
Tyr220) dramatically inhibit N7 methyl transfer activity in WNV
NS5MTase (Dong et al., 2008).
Based on the structure of MVEV NS5MTase in complex with
GpppA, which reveals a crystallographic dimer with two GpppA
molecules bound per monomer, Assenberg et al. (2007) proposed
Model 2. In this structure, the ﬁrst cap analogue binds in the HBS
with the adenosine base approaching the AdoMet binding pocket.
The secondanaloguebinds to the LBSand stacks against theﬁrst cap
analogue, with the guanosine base stacking against the adenosine
base of the ﬁrst analogue (Fig. 9) (Assenberg et al., 2007). Although
this indicates that theLBScanbindcapanalogues, supporting in this
way Model 1, the authors note that in the MVEV co-crystal struc-
ture the N7 and 2′O guanosine group of the two analogue bound
to the dimer are too far away (>10 and >8Å, respectively) from
M. Bollati et al. / Antiviral Research 87 (2010) 125–148 139
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cig. 9. Stereo view of the complex formed by MVEV NS5MTase with AdoHcy and t
nd interacting with the positively charged residues near the AdoMet-binding cleft
he AdoMet methyl leaving group to be catalytically relevant. This
asts some doubt over the catalytic relevance of the structure and
ndeed the signiﬁcance of the LBS in controlling N7MTase activity.
urther analysis of the crystallographic dimer show that two LBS
egions form a nearly continuous positively charged groove, with
he four GpppA molecules interacting in a manner resembling that
f a continuous strand of RNA. Based on this, Model 2 proposes that
he dimerization of two NS5MTase monomers generates a large
ositively charged RNA binding cleft that facilitates binding and
ranslocation of the capped RNA. As the RNA moves into the cat-
lytic site of the ﬁrstmonomer, N7methylation occurs, followed by
NA translocation via the LBS to the HBS of the second monomer
here 2′O methylation occurs. In this model the LBS acts merely as
n RNA-binding domain, in contrast to Model 1 discussed above.
.2.1.4. Functional characterization. Theﬁrst evidenceof enzymatic
ctivity from a ﬂavivirus NS5MTase domain was demonstrated
ith DENV NS5MTase using short capped RNA substrates
7me±GpppAC5 (Egloff et al., 2002). Such short substrates, even
tarting with GpppAG (the ﬁrst two nucleotides strictly conserved
n the 5′-end of the ﬂavivirus genome), support speciﬁcally the
′OMTase activity (Kroschewski et al., 2008; Lim et al., 2008). In
he context of the VIZIER Project, a protocol was set-up to pro-
uce pure N7me±GpppACn substrates of varying chain lengths
n=1–7) inhighamounts (Peyraneet al., 2007). The substrateswere
sed to prove 2′OMTase activity in a variety of ﬂavivirus NS5MTase
omains (Mastrangelo et al., 2007a; Bollati et al., 2009a,b) and
et-up inhibition assays (Luzhkov et al., 2007; Milani et al., 2009;
elisko et al., in press). Interestingly, it was found that DENV
′OMTase activity and binding increases with the substrate chain
ength until they reach a plateau at n=5. N7meGpppAC5 sub-
trateswere used to determine kinetic parameters of the 2′OMTase
ctivity of DENV NS5MTase (Selisko et al., in press). On the other
and, in order tomeasure N7MTase activity of ﬂavivirus NS5MTase
omains, a substrate of 74 nucleotides is needed, which contains a
onserved stem-loop structure (Ray et al., 2006; Dong et al., 2007).
n the context of VIZIER, capped subgenomic RNA of DENV was
roduced and used to demonstrate N7MTase activity of DENV and
ESSV NS5MTases (Milani et al., 2009). Moreover, in accordance
ith the hypothesis that the ﬂavivirus NS5MTase domain contains
he GTase activity, the WESSV NS5MTase domain was shown to
ovalently bind GMP at Lys28 (Bollati et al., 2009b). Following the
lassic scheme of cap formation (Furuichi and Shatkin, 2000) to
omplete the guanylyltransfer, GMP would be transferred to newlyolecules of GpppA: the ﬁrst cap analogue binds in the HBS, the second is adjacent
LBS (Assenberg et al., 2007).
synthesized ppRNA (see introduction). To date, however, there are
no available data fully proving the transfer of GMP on a ppRNA
substrate catalyzed by a ﬂavivirus NS5MTase domain.
3.2.2. NS5 RNA-dependent RNA polymerase domain
The ﬁrst structure of a ﬂavivirus NS5RdRp domain KUNV
NS5RdRp was determined within the VIZIER Project (Malet et al.,
2007). The low sequence identity of ﬂavivirus RdRps compared to
other RdRps with existing structures (Ferrer-Orta et al., 2005) pre-
cluded the use of themolecular replacementmethod. Starting from
a number of constructs of the KUNV NS5RdRp domain comprising
residues 273–905 with N- and C-terminal deletions, the structure
of a shorter form (317–905) could be solvedusing single anomalous
dispersion at 2.35Å resolution. This form of KUNV NS5RdRp then
allowed structure determination of the longer form (273–905) at
3.0Å resolution. The longer formwas enzymatically activewhereas
the shorter form was not (Malet et al., 2007). The KUNV NS5RdRp
structure then allowed the determination of the structure of the
NS5RdRp domain (starting at residue 273) of DENV3 NS5RdRp at
1.85Å resolution by molecular replacement (Yap et al., 2007).
3.2.2.1. General structural properties of the polymerase domain.
The structure of the two ﬂavivirus NS5RdRp domains have been
recently analyzed and reviewed in (Malet et al., 2008). They adopt
a typical RdRp right-hand structure comprising three subdomains:
ﬁngers, palm and thumb (Fig. 10). The ﬁngers subdomain of the
short KUNV NS5RdRp construct was partially disordered, whereas
the long constructs started with the ordered N-terminal helix
(277–287 and 275–285 for KUNV NS5RdRp and DENV NS5RdRp,
respectively). Both ﬂavivirus NS5RdRp domains display a closed
conformation, where ﬁngers and thumb subdomains are con-
nected. This is a characteristic of RdRps and in particular of
primer-independent (de novo) RdRps (reviewed in Ferrer-Orta
et al., 2005). A structural element named the priming loop pro-
vides the initiation platform. It belongs to the thumb subdomain
and points towards the active site in the palm. The active site is
located at the intersection of two tunnels. Other de novo RdRps
solved in complex with ssRNA template, NTPs and/or dsRNA prod-
uct (Butcher et al., 2001; Tao et al., 2002; O’Farrell et al., 2003)
suggest the following scenario shown in Fig. 10. The ﬁrst tun-
nel, located between the ﬁngers and the thumb, should allow the
ssRNA template to access the active site. The second tunnel, roughly
perpendicular to the ﬁrst, stretches across the entire protein. The
incoming NTP should arrive from the back of the tunnel and, after
140 M. Bollati et al. / Antiviral Research 87 (2010) 125–148
Fig. 10. Overview of the ﬂavivirus RdRp structure based on WNV NS5Pol (Malet et
al., 2007) as an example; a “Front” view is presented here in ribbon representation.
Fingers, palm and thumb subdomains are colored in blue, green and red, respec-
tively. The ssRNA template entry and the dsRNA exit are shown by black arrows. A
dotted arrow points to the NTP entry tunnel at the back of the RdRp. Motifs A, C,
E, F, the G-loop and the priming loop are colored in orange, yellow, grey, magenta,
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which could explain why the transition from initiation to elon-yan and purple, respectively. The Asp residues of catalytic motifs A and C (Asp-533,
sp-663 and Asp-664) are represented as stick models. N-ter and C-ter indicate the
ermini of the RdRp domain.
he polymerization has started, the nascent dsRNA should go out
hrough the front of this tunnel. However, as for other de novo
dRps, a conformational change is necessary to avoid a steric clash
ith the priming loop and allow neo-synthesized RNA to exit.
As expected, the most closely related structures are those of de
ovo RdRps from members of the Flaviviridae family, namely HCV
S5RdRp (Ago et al., 1999; Bressanelli et al., 1999; Lesburg et al.,
999) and bovine viral diarrhea virus (BVDV) NS5RdRp (Choi et al.,
004). They show sequence identities as low as 11–21%, depending
n the subdomainconsidered (Malet et al., 2007). Special featuresof
avivirusNS5RdRp structures are as follows (Malet et al., 2008): (1)
he ﬁngers subdomain was captured in a pre-initiation conforma-
ion since motif F, normally comprising the NTP-binding sites does
ot form the upper part of theNTP tunnel but is perpendicular to its
ormal position and partially disordered (Fig. 11). Additionally, the
ngers subdomain presents a loop, namedG-loop,which protrudes
owards the active site (see Fig. 11). It was given the name G-
oop because it harbours RdRp motif G in primer-dependent RdRps
Gorbalenyaet al., 2002; Ferrer-Ortaet al., 2004). This loopmayplay
regulatory role similar to the C-terminal in other RdRps (Adachi
t al., 2002; Leveque et al., 2003; Ng and Parra, 2004). In summary,
concerted conformational change of motif F and G-loop of the
rapped pre-initiation conformation is expected before ﬂavivirus
S5RdRp initiate RNA synthesis. (2) The priming loop is provided
y the thumb domain as observed for other de novo RdRps (bacte-
iophage phi6, HCV and BVDV RdRps (Ago et al., 1999; Bressanelli
t al., 1999; Lesburg et al., 1999; Butcher et al., 2001; Choi et al.,
004) but does not contain any secondary structure. Two aromatic
esidues Trp795 or His798 (DENV NS5RdRp), may act as initiation
latform stacking with the priming nucleotide. (3) Two Zn ions
ere found, one in theﬁngers andone in the thumbsubdomain. The
atter is localized at a supposed hinge position between the thumb
nd the palm subdomains. It might play a role in the regulation
f the conformational change between initiation and elongation
tate of ﬂavivirus NS5RdRps. (4) Two NLSs are present at the sur-
ace of the ﬁngers subdomain. They comprise the ﬁrst ﬁngertipFig. 11. Structural formulae of (a) ribavirin and (b) EICAR.
forming the connection between ﬁnger and thumb domain (see
Fig. 11), run across the back of the NS5RdRp domain and end in an
-helix, which comes to the front and forms the interface between
the bottom of the ﬁngers subdomain and the palm.
The NLS of DENV2 NS5 has been shown to be functional and the
transport of NS5 to the nucleus vital for virus replication (Pryor et
al., 2007). Especially two lysine residues at the beginning of the -
helix seem to be important. In contrast, KUNVNS5 does not localize
to the nucleus. Subtle differences in NLS geometry and charge dis-
tribution may be responsible for distinct behavior towards nuclear
import in closely related viruses, but this is not yet deducible from
the structures. It has not been shown if NS5 of DENV3 localizes to
the nucleus (Malet et al., 2008).
3.2.2.2. Three-dimensional structures determined for the ﬂaviviral
polymerase domain. TwoﬂavivirusNS5RdRpdomain structures are
known so far, KUNV NS5RdRp and DENV3 NS5RdRp (Malet et al.,
2007; Yap et al., 2007). The structures are very similar with an
r.m.s.d. of 1.9, 0.8 and 1.0Å (C atoms of matched residues) for
the ﬁngers, palm and thumb subdomains, respectively. The overall
r.m.s.d. is expected to be high because of a domain rotation based
on the hinge region between the thumb and the palm subdomains
near the Zn atom (see above). The rotation of the ﬁngers subdomain
by 8◦ leaves the DENV3 NS5RdRp structure more open in compari-
son to KUNV NS5RdRp. Another consequence is that the active site
of KUNV NS5RdRp is more tightly closed by the priming loop than
the active site of DENV3 NS5RdRp. KUNV NS5RdRp may need a
wider opening movement upon the transition to elongation mode,gation seems to be kinetically more limiting for KUNV NS5RdRp
compared to DENV2 NS5RdRp (Selisko et al., 2006).
Both ﬂavivirus NS5RdRp structures were obtained with a Mg2+
ion in a non-catalytic position near the active center. The role of the
l Research 87 (2010) 125–148 141
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on-catalytic ion is not known. It was proposed that it might play a
ole in the de novo initiationmechanism facilitating themovement
f the nascent dsRNA after formation of the ﬁrst dinucleotide out
f the active site (Butcher et al., 2001). DENV3 NS5RdRp crystals
ere soaked with the nucleotide analog 3′dGTP and the complex
tructure solved at 2.6Å resolution. Only the triphosphate moiety
f 3′dGTP is visible. Nevertheless, its position near the priming loop
nd in particular next to residue Trp795 lead to the proposal that
t represents the priming nucleotide and Trp795 acts as the initia-
ion platform (Yap et al., 2007). This is consistent with a model of
he de novo initiation complex of KUNV NS5RdRp, which assigned
he same Trp, conserved in all ﬂavivirus NS5 proteins, as initiation
latform (Malet et al., 2007).
.2.2.3. Characterization of polymerase activity. Within the VIZIER
roject, a comparison of steady-state enzymatic activity param-
ters of both full-length NS5 and NS5RdRp domain of DENV2
nd KUNV on a homopolymeric template poly(rC) suggested that
he NS5MTase domain does not inﬂuence de novo RdRp activity
Selisko et al., 2006; Zhang et al., 2008), although others did not
upport fully this view (Yap et al., 2007). The NS5RdRp domain
lone was used for screening processes and characterization of
nhibitors of the ﬂavivirus NS5RdRp activity. Furthermore, it has
een shown by atomic force microcopy that a NS5RdRp domain
f DENV2 with the same boundaries (272–900) binds to the cir-
ularized DENV2 RNA genome and that de novo RNA synthesis of
he negative strand is enhanced by the presence of a promoter ele-
ent, a large stem-loop structure, named SLA, present at the 5′-end
f the genome (Filomatori et al., 2006). The authors demonstrated
he physical interaction of the NS5RdRp domain with SLA. They
roposed a novel mechanism for −ssRNA synthesis in which the
avivirus NS5RdRp is recruited by and speciﬁcally binds SLA at the
′-end of the genome. It then reaches the site of initiation at the 3′-
nd recruited to the 5′-end via long-range RNA–RNA interactions.
The VIZIER Project contributed decisively to a precise identi-
cation of the ﬂaviviral NS5RdRp domain and to its subsequent
tructural characterization (Selisko et al., 2006; Malet et al., 2007;
ap et al., 2007). Our contributions will greatly facilitate the explo-
ation of the ﬂavivirus NS5RdRp as a drug target (Rawlinson et al.,
006; Malet et al., 2008), hopefully leading to the discovery and
esign of drugs against ﬂaviviruses.
. Antivirals
A safe and efﬁcient anti-ﬂavivirus/anti-DENV drug could poten-
ially beused for the treatment of patients living in endemic regions
nd presenting symptoms of DENV infection, as well as patients
ith laboratory-diagnosed DENV infection. Such drug may also be
f prophylactic relevance in case of an epidemic, in particular in
egions where more than one serotype is circulating. Another pos-
ible prophylactic use can be by travelers to and through endemic
egions and by personnel of NGOs working in endemic regions or
y military personnel carrying out humanitarian actions. Because
evere DENV disease has been associated with higher virus titres
Whitehead et al., 2007), reduction of viral replication may be
nstrumental to limit the risk of developing such symptoms.
The ideal ﬂavivirus drug should preferably be active against all
our DENV serotypes (and even other ﬂavivirus infections, such
s WNV and JEV). Such drug should be (i) administered via the
ral route and should thus have high oral bioavailability. Ideally, it
hould be (ii) administered only once or twice (maximum 3 times)
aily and (iii) have a high genetic barrier to resistance. Obviously,
iv) a drug that is to be used in the prophylactic setting as well as
n pediatric patients should be very safe. Moreover, since ﬂavivirus
rugs will be used in tropical regions, the drug should also haveFig. 12. Mechanism of ribavirin action. Target enzyme: IMP dehydrogenase. Rib-
avirin 5′ monophosphate inhibits the conversion of IMP to XMP resulting in a
reduced supply of GTP, and, indirectly, also a reduced supply of ATP.
(v) good thermal stability and a good hygroscopic parameter (high
temperature and level of humidity). Moreover, (vi) the production
should be “easy” and low-cost (limited number of chemical steps
and common availability of the starting material).
4.1. A broad-spectrum antiviral molecule with weak activity
Ribavirin (1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxam-
ide, Fig. 11a) is a broad-spectrum inhibitor of RNA viruses replica-
tion proved to treat HCV infections, in combination with pegylated
interferon and in aerosol form, for the treatment of pediatric res-
piratory syncytial virus (RSV) infections. Ribavirin has also been
used experimentally against a number of other conditions, includ-
ing Lassa fever, Crimean-Congo hemorrhagic fever virus (CCHFV),
and hantaviruses (Ergonul, 2008; Jonsson et al., 2008; Khan et al.,
2008). Almost all RNA viruses and even some DNA viruses are sen-
sitive to the in vitro antiviral activity of ribavirin. Some viruses are
more susceptible to the action of ribavirin than others; ﬂaviviruses,
for example, are much less sensitive than the paramyxovirus RSV
(Leyssen et al., 2005).
The antiviral activity of ribavirin was reported almost four
decadesago, but themolecularmechanismbywhich the compound
exerts its antiviral activity still remains a matter of debate. Inosine
5′-monophosphate (IMP) dehydrogenase, a cellular enzyme which
converts IMP to xanthosine 5′-monophosphate in the de novo syn-
thesis pathway of GMP, is inhibited by ribavirin 5′-monophosphate
(Streeter et al., 1973). As a consequence, intracellular GTP pools are
depleted, resulting in inhibition of viral (but also cellular) RNA syn-
thesis (Fig. 12). Several other mechanisms have been proposed to
contribute to the antiviral activity of ribavirin, including inhibition
of viral capping (via an effect on the viral GTase orMTase activities)
(Benarroch et al., 2004; Bougie and Bisaillon, 2004), and inhibition
of RdRp activity by the 5′-triphosphate group of the drug (Maag et
al., 2001; Bougie and Bisaillon, 2003). Moreover, inhibition of the
viral helicase activity by ribavirin has been proposed for reoviruses
(Rankin et al., 1989).
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Poliovirus cultured in the presence of ribavirin (concentrations
p to 1mM) accumulatedmutations in its genome, a process called
rror catastrophe (Crotty et al., 2001). For ﬂaviviruses we demon-
trated that GTP pool depletion is the predominant mechanism by
hich ribavirin exerts its antiviral activity (Leyssen et al., 2005) and
hat an error catastrophe based mechanism does not contribute to
he in vitro antiviral activity of the drug (Leyssen et al., 2006). The
ffect of ribavirinwas studied in rhesusmonkeys infectedwith YFV
r DENV1. Either therapeutic or prophylactic protocols were stud-
ed. Overall, no effect on viremia and survival was noted (Huggins
t al., 1984; Huggins, 1989; Malinoski et al., 1990). Since the mech-
nism of anti-ﬂavivirus activity of ribavirin is based on an aspeciﬁc
echanism, the design of safe and more potent analogues of rib-
virin will likely be very difﬁcult to achieve. EICAR (Fig. 11b), the
-ethynyl analogue of ribavirin, was shown to be roughly 10–20-
old more potent in inhibiting ﬂaviviruses replication in vitro. This
mproved activity came, however, at the price of a concomitant
ncrease in toxicity (Leyssen et al., 2005), which is explained by the
act that EICAR 5′-monophosphate is also more potent in inhibiting
he IMP dehydrogenase (Balzarini et al., 1993). Recently, a hetero-
yclic molecule with in vitro anti-DENV activity was reported; the
echanism of action was suggested to be related to the inhibition
f cellular IMP dehydrogenase (Nair et al., 2009).
.2. Selective inhibitors of viral replication
TheHCVRdRp has been shown to be an excellent target for inhi-
ition of viral replication. In fact, numerous selective inhibitors of
CV replication that target this enzyme have been identiﬁed so far.
hese compounds can largely been classiﬁed as nucleoside (that
eed to be phosphorylated to their 5′-triphosphate metabolite)
nd non-nucleoside inhibitors (that act as allosteric site inhibitors)
De Clercq and Neyts, 2009). The nucleoside HCV inhibitors 2′-
-methylcytidine (Fig. 13a), and related 2′-C-methyl nucleosides,
nhibit the replication of a broad spectrum of (+)ssRNA viruses
ncluding ﬂaviviruses (Eldrup et al., 2004). Another nucleoside
nhibitor, i.e. 4′-azidocytidine (Fig. 13b), is solely active against
CV and does not show activity against ﬂaviviruses and other RNA
iruses (Klumppet al., 2006, andunpublisheddata). It remains tobe
tudied what is the structural basis for the broad-spectrum activity
ersus RNA viruses of the 2′-C-methyl nucleoside analogues and
he lack of activity of the 4′-azido nucleoside analogues.tidine, (b) 4′-azidocytidine and (c) T-705.
Recently, a substituted pyrazine (T705, Fig. 13c) has been
reported to be a potent inhibitor against inﬂuenza A, B and
C viruses in vitro (Furuta et al., 2002, 2005). It has been
proposed that T-705 is converted intracellularly to the ribonu-
cleotide T-705-ribofuranosyl-5′-monophosphate (T-705 RMP) by
a phosphoribosyl transferase, and, upon phosphorylation, to its
5′-triphosphate. This metabolite would inhibit the inﬂuenza virus
RdRp in a GTP-competitive manner (Furuta et al., 2002, 2005).
Unlike ribavirin 5′-monophosphate, T-705 RMP does not signiﬁ-
cantly inhibit IMP dehydrogenase, indicating that it may owe its
anti-inﬂuenza virus activity mainly, if not exclusively to inhibi-
tion of the inﬂuenza virus RNA polymerase. Surprisingly, T-705
has also been accredited with both activity against other viruses,
i.e. arenaviruses (Pichinde), and bunyaviruses (Punta Toro) and ﬂa-
viviruses. In addition to inhibitingYFVandWNVreplication in vitro,
improvements in survival and disease parameters were observed
also after addition of T-705 to YFV- or WNV-infected rodents
(Morrey et al., 2008; Julander et al., 2009). It may be assumed
that the mechanism by which T-705 inhibits viruses other than
inﬂuenza is similar to the mechanism by which it is believed to
inhibit inﬂuenza virus replication. This remains subject of further
studies. Such studies may also provide insight on how broad-
spectrum inhibitors of RNA viruses encompassing both (−)ssRNA
and (+)ssRNA viruses should be designed,.
So far, non-nucleoside inhibitors of ﬂavivirus replication which
target the viral NS5RdRp domain have not yet been reported.
Within the VIZIER Project, potential allosteric inhibitor binding
sites were predicted on the NS5RdRp of DENV and WNV, using
two different programs (Malet et al., 2008). Since several classes of
non-nucleoside inhibitors of pestiviruses and HCV RdRp (and four
allosteric binding sites) have been identiﬁed, it may be assumed
that this class of inhibitors may also have potential against ﬂa-
viviruses.
4.3. Identiﬁcation of novel antivirals
As outlined above, target-based design of inhibitors of ﬂavivirus
replication may be a promising strategy towards the development
of selective anti-ﬂaviviral drugs. Another strategy, with a proven
success in the development of inhibitors of for example HIV, her-
pes and HCV, has been based on the screening of large libraries
of molecules. Infected-cell-based screening assays offer the advan-
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age that (i) novel targets for antiviral therapy in the replication
ycle of the virus that would not have been discovered in target-
ased assays may be identiﬁed, and (ii) compounds that do not
nter the host cell or that are toxic to the host cell will be excluded
or further validation. Several examples of antiviral drugs that
ould not have been identiﬁed in target-based screenings assays
nclude (i) the BVDV non-nucleoside inhibitors (VP32947, BPIP,
G110, LZ37) that target the viral RdRp, but that do not exhibit
nhibitory activity on the puriﬁed RdRp, (ii) the imidazopyridines
ith anti-HCV activity, of which one analogue (GS-9190), target-
ng the HCV RdRp but not inhibiting the activity of the puriﬁed
nzyme, is currently inphase II clinical studies (Vliegenet al., 2009),
nd (iii) the cyclophilin-bindingagentDebio-025, apotent inhibitor
f HCV replication (currently in phase II clinical studies) that pre-
ents HCV replication by interfering with cyclophilins (which are
ssential in the replication cycle of HCV), but that has not been
hown to directly inhibit a particular enzymatic function of the
irus (Chatterji et al., 2009; Coelmont et al., 2009).
.3.1. High-throughput screening approach
Most ﬂaviviruses that are pathogenic to humans, readily cause a
yto-pathogenic effect (CPE) in cell culture, being thus amenable to
igh-throughput screening programs. Compounds to be screened
houldnot containpotential toxic functions, shouldnot haveunsta-
le chemical groups, or poor solubility, and should ideally comply
ith Lipinski’s rule of ﬁve or the Veber rules. Furthermore, the
ibrary can be enriched for drug-like compounds (Comprehensive
edicinal Chemistry mapping). To identify molecules with poten-
ial in vitro anti-DENV activity (hit compounds), a primary screen
s run (using multiple dilutions/compound to exclude too many
alse positives) and the potential inhibitory effect on virus-induced
PE is quantiﬁed [employing a luminescence-based metabolic
ssay (ATP-lite)]. Concomitantly with the evaluation of the antivi-
al effect, the potential anti-metabolic effect of the compounds
n uninfected cells is quantiﬁed [employing an absorbance-based
etabolic assay]. Once hit compounds have been identiﬁed, the
ntiviral activity and selectivity need to be conﬁrmed using a
ewly synthesized batch of the molecule. Next, the antiviral activ-
ty, either based on quantifying the effect of the compound on the
nfectious virus-yield and/or the effect on viral RNA production, is
onﬁrmed in virus-yield assays. Once this has been accomplished,
hit-to-lead optimization process can be initiated, given the fact
hat the compound class is chemically tractable.Meanwhile studies
o characterize the antiviral activity and to identify the molecular
arget are performed.
Within the VIZIER consortium, two compound classes with
ntiﬂavivirus activity were identiﬁed. A ﬁrst compound, SA-17,
dentiﬁed as a potent inhibitor of ﬂavivirus replication, is an
nalogue of doxorubicin (an antineoplastic antibiotic from Strep-
omyces peucetius) that carries a squaric acid amide-ester moiety
t the carbohydrate (-l-daunosaminyl) of doxorubicin. It should
e mentioned that this molecule does not comply with the Lipin-
ki rule of ﬁve. SA-17 was found to have excellent activity against
ENV (EC50=0.3g/ml) and is markedly less cytostatic than the
arent compound (CC50=28g/ml). SA-17 also inhibited YFV-17D
eplication, although less efﬁciently than DENV replication, but
roved inactive against other viruses (the picornavirus coxsack-
evirus B3, the retroviruses HIV-1 and HIV-2, and the herpesvirus
SV-1). SA-17 inhibits ﬂavivirus replication in Vero cells in a dose-
ependentmanner, as assessed by virus-yield reduction assays and
uantiﬁcation of viral RNA by means of q-RT-PCR. The anti-DENV
ctivity was conﬁrmed using a Renilla luciferase expressing DENV
eporter. Time-of-drug addition studies revealed that SA-17 acts
t the very early stages of the viral replication cycle. This obser-
ation was corroborated by the observation that SA-17, unlike the
ucleoside analogue ribavirin, does not inhibit the replication ofarch 87 (2010) 125–148 143
DENV subgenomic replicons. Preincubation of high-titre DENV or
YFV-17D stocks with 5 or 10g/ml SA-17 for 1h resulted in 100%
inhibition of viral infectivity. Inhibition of viral infectivity by SA-17
in such pre-incubation experiments correlates with the antiviral
effect obtained in virus-yield assays. Molecular modeling studies
identiﬁed a putative binding site for SA-17 in the DENV glycopro-
tein E (Kaptein et al., submitted for publication).
A second compound class, identiﬁed in a large screening effort,
consists of a series of small drug-like molecules that inhibit the
replication of both YFV and DENV2 replication (representative
molecule CHI-104). Unlike SA-17, it appeared from time of drug
addition studies that this class of compounds interferes with a step
in the replication cycle of ﬂaviviruses that coincides with the onset
of viral RNA synthesis. This was corroborated by the observation
that the compounds are active (like the reference compound rib-
avirin, but unlike compound SA-17 that acts at an early stage of
the replication cycle) in the DENV subgenomic replicon system.
Currently, drug-resistant variants against CHI-104 (and analogues)
are being generated. It is expected that drug-resistant variants will
carry mutations in the NS genes encoded by the replicon. Reintro-
duction of the mutations identiﬁed in drug-resistant viruses in the
wild-type genome should result in a resistant phenotype. Once the
target has been identiﬁed using this approach, the gene of interest
will be expressed and, if an enzymatic activity is associated with
this protein, a potential inhibitory activity of the compound (class)
on this protein will be studied. If a crystal structure of the target
protein is available, this should allow to deﬁne (based on soaking
or co-crystallization experiments with subsequent complex struc-
turedetermination) theprecisemolecular interactionsbetween the
inhibitor and the target. In turn, this will allow a rational approach
to optimize the antiviral activity/selectivity.
4.3.2. Virtual docking of small molecules
In the context of the VIZIER Project, about one hundred crys-
tal structures of important enzymes relevant for viral replication
have been determined. The 3D structure of an enzyme, and, in par-
ticular, of its active site, can be an useful tool to identify possible
inhibitors of the target protein. In virtual docking, a library of small
molecules is used to identify ligands with high binding afﬁnity to
the protein active site. In VIZIER Project, in order to ﬁnd new ﬂa-
vivirus inhibitors, many efforts have been spent on the study of
the NS5MTase enzyme. In particular, the binding site of its cofactor
AdoMetwas used to screen a set of 7836 potential ligand structures
by virtual docking (Luzhkov et al., 2007). The structures were gen-
erated by geometry optimization and ligand preparation of 2566
hits that had been selected from a data base of 2.1 million com-
mercially available compounds after conducting a pharmacophore
and a 2D similarity search. One of the top binders was found to
inhibit the 2′OMTase activity of DENVNS5MTasewith an IC50 value
of 60.5M. Another approach for NS5MTase inhibition was based
on the mechanism of action of the enzyme. In this case, the virtual
search was directed to ﬁnd molecules potentially able to bind to
the protein active site in presence of the AdoMet cofactor. In the
latter approach, it was chosen not to interfere with the binding of
the cofactor to the protein but with the methyl transfer activity
(Milani et al., 2009). Therefore, virtual screening of a compounds
library yielded a ligand capable to bind to the NS5MTase active
site in presence of AdoMet. Such a ligand can interfere with the
methyl transfer activity of the enzyme because of steric hindrance
in the active site. In both cases, inhibition of AdoMet binding site
or hindrance of the enzyme active site, the two molecules identi-
ﬁed showed activity against the enzyme (N7MTase and 2′OMTase
activities). The potential use of the two new inhibitors against viral
replication is still under investigation.
In addition to the components of the ﬂaviviral replicase com-
plex, the protease is also of high interest as a target for new
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ntivirals (see Section 3.1.1 above). Here, some lessons can be
earned from drug discovery efforts performed in order to inhibit
he proteases of HCV and HIV, both well established drug targets.
s varioushigh-throughput screeningattemptsdidnotproduce the
riginally sought results, researchers chose structure-based design
trategies to develop potent inhibitors. This resulted in impres-
ive success stories (Anderson et al., 2009; Lamarre et al., 2003;
santrizos, 2004). Similar strategies are currently being applied to
he ﬂavivirus NS2B/NS3 proteases, not only in academic laborato-
ies, but increasingly also in the pharmaceutical industry.
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